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1  Alzheimer’s Clinical Trials Update 
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Disease 
   
Thursday 4:15 pm 4  Poster Session and Wine & Cheese 
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Thursday 7:30 pm 5  Submitted Abstracts 
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PROGRAM 
 
 
WEDNESDAY, December 1—7:30 PM 
 
 
SESSION 1 ALZHEIMER'S CLINICAL TRIALS UPDATE 
 
Chairperson: S. Gandy, Mount Sinai School of Medicine, New York,  
  New York 
 
WELCOME 
 
Jeff Rothstein 
Johns Hopkins University School of Medicine 
 
 
Bapineuzumab immunotherapy for Alzheimer's disease 
Michael Grundman. 
Presenter affiliation: Janssen Alzheimer Immunotherapy, South San 
Francisco, California. 
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Norm Relkin. 
Presenter affiliation: Cornell University Medical College, New York, 
New York. 
 
  
Andrew Protter. 
Presenter affiliation: Medivation, Inc., San Francisco, California. 
 
  
Therapy persistence with disease-modifying AD therapy—Impact 
on NNT and AD-free years in an asymptomatic population 
Nicolas M. Furiak, Timothy M. Klein, Megha Bansal, Robert W. Klein. 
Presenter affiliation: Medical Decision Modeling Inc, Indianapolis, 
Indiana. 
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 vi 
THURSDAY, December 2—9:00 AM 
 
 
SESSION 2 BIOMARKERS AND GENETICS 
 
Chairperson: V. Lee, University of Pennsylvania School of Medicine,  
  Philadelphia 
 
 
Robert Dean. 
Presenter affiliation: Eli Lilly and Company, Indianapolis, Indiana. 
 
  
Radiopharmaceuticals for detection of pathological protein 
aggregates in neurodegenerative diseases 
Franz Hefti, Chris M. Clark, Mark A. Mintun, Michael J. Pontecorvo, 
Daniel M. Skovronsky. 
Presenter affiliation: Avid Radiopharmaceuticals, Philadelphia, 
Pennsylvania. 
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Perspectives for the future development of neuropathology—
Biomarkers for Alzheimer’s disease, Parkinson’s disease and 
related disorders 
John Q. Trojanowski. 
Presenter affiliation: University of Pennsylvania, Philadelphia, 
Pennsylvania. 
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Gerald Schellenberg. 
Presenter affiliation: University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania. 
 
  
Andrew Singleton. 
Presenter affiliation: National Institutes of Health, Bethesda, Maryland. 
 
  
Genome-wide association study of frontotemporal lobar 
degeneration with TDP-43 inclusions 
Vivianna Van Deerlin, Patrick Sleiman, Maria Martinez-Lage, Alice 
Chen-Plotkin, Li-San Wang, Gerard Schellenberg, Hakon Hakonarson, 
John Q. Trojanowski, Virginia M. Lee, and the International 
Collaboration on FTLD. 
Presenter affiliation: University of Pennsylvania, Philadelphia, 
Pennsylvania. 
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 vii 
THURSDAY, December 2—2:00 PM 
 
 
SESSION 3 RNA METABOLISM IN NEURODEGNERATIVE DISEASE 
 
Chairperson: J. Rothstein, Johns Hopkins University School of Medicine,  
  Baltimore, Maryland 
 
  
Correction of SMN2 RNA splicing in the CNS as a therapeutic 
strategy for spinal muscular atrophy 
Yimin Hua, Kentaro Sahashi, Gene Hung, Frank Rigo, Marco Passini, 
C Frank Bennett, Adrian R. Krainer. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York. 
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RNA maps in human neurodegenerative disease 
Robert B. Darnell. 
Presenter affiliation: Rockefeller University/HHMI, New York, New 
York. 
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Virginia Lee. 
Presenter affiliation: University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania. 
 
  
Deciphering the role of TDP-43 in ALS/FTLD and other 
neurodegenerative disorders 
Robert H. Baloh. 
Presenter affiliation: Washington University in St. Louis, St. Louis, 
Missouri. 
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RNA binding proteins and frontotemporal lobar degeneration 
Rocky Gao, Tanya Monahiem, Amar Kar, Kazuo Fushimi, Jane Y. Wu. 
Presenter affiliation: Northwestern University, Chicago, Illinois. 
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 viii 
THURSDAY, December 2—4:15 PM 
 
 
SESSION 4 POSTER SESSION and WINE & CHEESE PARTY 
 
  
Defining the role of DBR1 as a potent modifier of TDP-43 
mediated toxicity in ALS 
Maria Armakola, Aaron D. Gitler. 
Presenter affiliation: University of Pennsylvania, Philadelphia, 
Pennsylvania. 
 
 
 
 
10 
  
Disease-linked mutant human TDP-43 accumulated to moderate 
levels causes late onset motor neuron deficits in mice 
Eveline S. Arnold, Michael Hefferan, Shuo-Chien Ling, Clotilde Lagier-
Tourenne, Magdalini Polymenidou, Dara Ditsworth, Martin Marsala, 
Don W. Cleveland. 
Presenter affiliation: UC San Diego, La Jolla, California; Ludwig 
Institute for Cancer Research, La Jolla, California. 
 
 
 
 
 
 
11 
  
A non-active site, function-blocking anti-BACE1 antibody that 
significantly reduces Abeta production in vivo 
Jasi Atwal, Yongmei Chen, Cecilia Chiu, Scott Stawicki, Chris Heise, 
Yichin Liu, Yanmei Lu, Deborah Mortensen, Kimberly Scearce-Levie, 
Yingnan Zhang, Bob Lazarus, Weiru Wang, Yan Wu, Marc Tessier-
Lavigne, Ryan J. Watts. 
Presenter affiliation: Genentech, South San Francisco, California. 
 
 
 
 
 
 
12 
  
Procaspase-activating compound 1 induces a caspase-3-
dependent cell death in cerebellar granule neurons 
Gulzeb Aziz, Øyvind W. Akselsen, Trond V. Hansen, Ragnhild E. 
Paulsen. 
Presenter affiliation: Gulzeb Aziz, OSLO, Norway. 
 
 
 
 
13 
  
Variation in the age at onset of Machado-Joseph disease—The 
influence of the APOE polymorphism 
Conceição Bettencourt, Mafalda Raposo, Cristina Santos, Teresa Kay, 
João Vasconcelos, Patrícia Maciel, Manuela Lima. 
Presenter affiliation: University of the Azores, Ponta Delgada, Portugal; 
University of Porto, Porto, Portugal; University Complutense of Madrid, 
Madrid, Spain. 
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 ix 
Modelling motor neuron disease using induced pluripotent stem 
cells 
Bilada Bilican, Andrea Serio, Gareth J. Sullivan, Agnes Nishimura, In-
Hyun Park, Judy Fletcher, Clare Puddifoot, David Story, Monica 
Carrasco, Giles Hardingham, George Q. Daley, Ian Wilmut, Tom 
Maniatis, Chris E. Shaw, Siddharthan Chandran. 
Presenter affiliation: Euan MacDonald Centre for Motor Neurone 
Disease Research, Edinburgh, United Kingdom; Centre for 
Neuroregeneration, Edinburgh, United Kingdom; MRC Centre for 
Regenerative Medicine, Edinburgh, United Kingdom. 
 
 
 
 
 
 
 
 
 
15 
  
Regulation of TDP-43 aggregation by phosphorylation and 
autophagy pathway 
Owen A. Brady, Peter S. Meng, Yanqiu Zheng, Yuxin Mao, Fenghua 
Hu. 
Presenter affiliation: Cornell University, Ithaca, New York. 
 
 
 
 
16 
  
PINK1 deficiency results in abnormal dopamine homeostasis and 
affects innate immune and cell survival signaling 
Ravi S. Akundi, Zhenyu Huang, Joshua Eason, Jignesh D. Pandya, 
Wayne A. Cass, Lianteng Zhi, Patrick G. Sullivan, Hansruedi Büeler. 
Presenter affiliation: University of Kentucky, Lexington, Kentucky. 
 
 
 
 
17 
  
Covalent modification of ubiquitin E1 activating enzyme by N,N-
diethyldithiocarbamate produces altered protein processing and 
dopaminergic toxicity in the rat 
Samuel W. Caito, Olga M. Viquez, William M. Valentine. 
Presenter affiliation: Vanderbilt University Medical Center, Nashville, 
Tennessee. 
 
 
 
 
 
18 
  
TGF-β induces TIAF1 self-aggregation via type II receptor-
independent signaling that leads to generation of amyloid β 
plaques in Alzheimer’s disease 
Ming-Hui Lee, Sing-Ru Lin, Jean-Yun Chang, Nan-Shan Chang. 
Presenter affiliation: National Cheng Kung University College of 
Medicine, Tainan, Taiwan; SUNY Upstate Medical University, 
Syracuse, New York. 
 
 
 
 
 
 
19 
  
Exome sequencing of an FTLD-TDP family to identify a new 
disease gene 
Alessandra Chesi, Yun (Rose) Li, Vivianna M. Van Deerlin, Aaron D. 
Gitler. 
Presenter affiliation: University of Pennsylvania, Philadelphia, 
Pennsylvania. 
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 x 
Progranulin modulates neuron development in zebrafish 
Babykumari P. Chitramuthu, David C. Baranowski, Denis G. Kay, 
Andrew Bateman, Hugh P. Bennett. 
Presenter affiliation: McGill University, Montreal, Canada; Neurodyn 
Inc, Charlottetown, Canada. 
 
 
 
 
21 
  
RANBP2-medicated neuroprotection causes the modulation of 
protein-lipid homeostasis of functionally diverse but linked 
pathways in response to oxidative stress 
Kyoung-in Cho, Paulo A. Ferreira. 
Presenter affiliation: Duke University Medical Center, Durham, North 
Carolina. 
 
 
 
 
 
22 
  
Neural induction with a proneural gene enhance the therapeutic 
functions of mesenchymal stem cells in ALS mouse model 
Chan-Il Choi, Young-Don Lee, Haeyoung Suh-Kim, Sung-Soo Kim. 
Presenter affiliation: Ajou University, School of Medicine, Suwon, 
South Korea. 
 
 
 
 
23 
  
Biochemical characterization of full-length human recombinant 
LRRK1 and LRRK2 
Laura Civiero, Elisa Greggio, Jean-Marc Taymans, Alexandra Beilina, 
Mark R. Cookson, Veerle Baekelandt, Luigi Bubacco. 
Presenter affiliation: University of Padova, Padova, Italy. 
 
 
 
 
24 
  
A yeast functional screen predicts new ALS disease genes 
Julien Couthouis, Renske Erion, Michael P. Hart, Zamia Diaz, Tadashi 
Nakaya, Fadia Ibrahim, Oliver D. King, Hyung-Jun Kim, Felix Geser, 
Virginia M.Y. Lee, John Q. Trojanowski, Hakon Hakonarson, Nancy M. 
Bonini, James Shorter, Vivianna M. Van Deerlin, Zissimos Mourelatos, 
Aaron D. Gitler. 
Presenter affiliation: University of Pennsylvania, Philadelphia, 
Pennsylvania. 
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Small molecule antagonists of toxic β-amyloid assemblies 
Mimi Cushman, Huan Wang, Jacob E. Lazarus, Brett Fors, Stephen L. 
Buchwald, James Shorter. 
Presenter affiliation: University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania. 
 
 
 
 
26 
  
TDP-43 pathology in ALS—Investigating loss- and gain-of-
function in Drosophila. 
Tanya R. Da Sylva, Miluska Jauregui, Michael K. Garroni, Gabrielle L. 
Boulianne. 
Presenter affiliation: The Hospital for Sick Children, Toronto, Canada. 
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 xi 
Characterisation of the IgG129-saporin lesioned rat as an animal 
model for cholinergic neuropathology and cognitive decline in 
Alzheimer’s disease 
Annette K. Mortensen, Inge E. de Jong, Niels Plath. 
Presenter affiliation: H. Lundbeck A/S, Valby, Denmark. 
 
 
 
 
28 
  
Cell autonomous alterations due to mutant TDP-43 expression in 
motor neurons derived from mouse embryonic stem cells 
Dara Ditsworth, Wesley Gifford, Todd Macfarlan, Eveline S. Arnold, 
Samuel L. Pfaff, Don W. Cleveland. 
Presenter affiliation: Ludwig Institute for Cancer Research, La Jolla, 
California; University of California, San Diego, La Jolla, California. 
 
 
 
 
 
29 
  
Loss of sortilin cause increased survival of retinal ganglion cells 
in a mouse model of transiently increased intraocular pressure 
Christian Schmeer, Rikke Madsen, Marlene Q. Jørgensen, Anders 
Nykjær Anders, Anders B. Elvang. 
Presenter affiliation: H. Lundbeck A/S, Valby - Copenhagen, Denmark. 
 
 
 
 
30 
  
A genetic screen for dominant suppressors of pink1 in 
Drosophila melanogaster 
Giovanni Esposito, Melissa Vos, Sven Vilain, Onno Schaap, Patrik 
Verstreken. 
Presenter affiliation: VIB, Leuven, Belgium. 
 
 
 
 
31 
  
Astrocytic redox remodeling by amyloid β peptide 
Sanjay K. Garg, Victor M. Vitvitsky, Ruma Banerjee. 
Presenter affiliation: University of Michigan, Ann Arbor, Michigan. 
 
 
32 
  
Loss of ALS2/alsin aggravates motor dysfunction in a mutant 
SOD1-expressing mouse ALS model by disturbing the 
endolysosomal system 
Shinji Hadano, Asako Otomo, Ryota Kunita, Kyoko Suzuki-
Utsunomiya, Akira Akatsuka, Masato Koike, Masashi Aoki, Yasuo 
Uchiyama, Yasuto Itoyama, Joh-E Ikeda. 
Presenter affiliation: Tokai University School of Medicine, Kanagawa, 
Japan. 
 
 
 
 
 
 
 
33 
  
Insights into TDP-43 proteinopathy using Drosophila 
melanogaster as a model system. 
Keith A. Hanson, Sang Hwa Kim, David A. Wassarman, Randal S. 
Tibbetts. 
Presenter affiliation: University of Wisconsin-Madison, Madison, 
Wisconsin. 
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 xii 
Developing applications for primary astrocytes to enable drug 
discovery 
Spencer Hermanson, Lucas Chase, Kun Bi. 
Presenter affiliation: Life Technologies Corporation, Madison, 
Wisconsin. 
 
 
 
 
35 
  
Cathepsin B inhibition reduces brain β-amyloid peptides while 
increasing brain BACE1 activity in animal models expressing APP 
with the normal β-secretase site sequence 
Greg Hook, Vivian Hook, Mark Kindy. 
Presenter affiliation: American Life Science Pharmaceuticals, San 
Diego, California. 
 
 
 
 
 
36 
  
Pharmacogenetic features of inhibitors to cathepsin B that 
improve memory deficit and reduce beta-amyloid related to 
Alzheimer’s disease 
Vivian Hook, Mark Kindy, Lydiane Funkelstein, Gregory Hook. 
Presenter affiliation: University of California, San Diego, La Jolla, 
California. 
 
 
 
 
 
37 
  
Genomic profile of Toll-like receptor pathways in traumatically 
brain- injured mice—Effect of exogenous progesterone 
Fang Hua, Jun Wang, Tauheed Ishrat, Wenjing Wei, Fahim Atif, Iqbal 
Sayeed, Donald G. Stein. 
Presenter affiliation: Emory University, Atlanta, Georgia. 
 
 
 
 
38 
  
Determining the physiological role of TDP-43 in the central 
nervous system 
Yun Ha Jeong, Philip C. Wong. 
Presenter affiliation: The Johns Hopkins University School of Medicine, 
Baltimore, Maryland. 
 
 
 
 
39 
  
Structural insights into allosteric inhibition of GluN2B N-methyl-
D-aspartate (NMDA) receptors 
Erkan Karakas, Noriko Simorowski, Hiro Furukawa. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York. 
 
 
 
 
40 
  
WASP is activated by phosphatidylinositol-4,5-bisphosphate to 
restrict synapse growth in a pathway parallel to bone 
morphogenetic protein signaling. 
Thang M. Khuong, Ron L. Habets, Jan R. Slabbaert, Patrik Verstreken. 
Presenter affiliation: VIB, Leuven, Belgium; K.U.Leuven, Center for 
Human Genetics, Leuven, Belgium. 
 
 
 
 
 
41 
  
 xiii 
ALS-associated proteins TDP-43 and FUS/TLS function in a 
common biochemical complex 
Sang Hwa Kim, Naval P. Shanware, Michael J. Bowler, Randal S. 
Tibbetts. 
Presenter affiliation: University of Wisconsin-Madison, Madison, 
Wisconsin. 
 
 
 
 
 
42 
  
Roles of BACE-1 and Cathepsin B in the generation of Aβ peptide 
in Alzheimer’s disease 
Mark S. Kindy, Jin Yu, Hong Zhu, Salim El-Amouri, Greg Hook, Vivain 
Hook. 
Presenter affiliation: Medical University of South Carolina, Charleston, 
South Carolina; Ralph H. Johnson VA Medical Center, Charleston, 
South Carolina. 
 
 
 
 
 
 
43 
  
Sonic Hedgehog signaling is essential for the maintenance of 
cellular homeostasis within the adult nigro-striatal microcircuit 
Luis E. Gonzalez, Miguel Verbitsky, Daniel Paredes, Andreas H. 
Kottmann. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
44 
  
TDP-43 phosphorylation drives neurotoxicity in a C. elegans 
model of TDP-43 proteinopathy 
Brian C. Kraemer, Nicole F. Liachko, Chris R. Guthrie. 
Presenter affiliation: Veterans Affairs Puget Sound Health Care 
System, Seattle, Seattle, Washington; University of Washington, 
Seattle, Washington. 
 
 
 
 
 
45 
  
Inhibition of EGFR in an ALS mouse model delays synapse 
elimination in early disease 
Claire Le Pichon, Sara Dominguez, Hilda Solanoy, Kimberly Scearce-
Levie. 
Presenter affiliation: Genentech, South San Francisco, California. 
 
 
 
 
46 
  
Evaluating Trinucleotide Repeat Expansions in ALS 
Teresa T. Lee, Michael P. Hart, Yun Li, Daniel Ramos, Niti Jethava, 
Divya Hosangadi, Jake Epstein, Brittany Hodges, Nancy M. Bonini, 
Aaron D. Gitler. 
Presenter affiliation: University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania. 
 
 
 
 
 
47 
  
 xiv 
Elevated expression of wild type and ALS-linked mutations in 
FUS/TLS triggers neurodegeneration in mice 
Shuo-Chien Ling, Philippe Parone, Sandrine Da Cruz, Hristelina Ilieva, 
Michael Hefferan, Desiree L. Salazar, Debbie Swing, Lino Tessarollo, 
Martin Marsala, Christopher E. Shaw, Don W. Cleveland. 
Presenter affiliation: University of California at San Diego (UCSD), La 
Jolla, California. 
 
 
 
 
 
 
48 
  
Formation of an RNA/DNA hybrid R-Loop at the human FMR1 
5'UTR 
Erick W. Loomis, Frederic Chedin, Paul J. Hagerman. 
Presenter affiliation: University of California Davis School of Medicine, 
Davis, California. 
 
 
 
 
49 
  
Genetic and pharmacologic modulation of the IIS and HSF-1 
pathways rescues mutant ataxin-3-mediated proteotoxicity in C. 
elegans neurons 
Andreia Teixeira-Castro, Michael Ailion, Ana Jalles, Andreia Neves-
Carvalho, Richard I. Morimoto, Patricia Maciel. 
Presenter affiliation: University of Minho, Braga, Portugal. 
 
 
 
 
 
50 
  
Characterization of a novel transgenic mouse model of Machado-
Joseph disease 
Sara Duarte-Silva, Anabela Silva-Fernandes, Andreia Neves-Carvalho, 
Andreia Teixeira-Castro, Pedro Oliveira, Patricia Maciel. 
Presenter affiliation: University of Minho, Braga, Portugal. 
 
 
 
 
51 
  
A neurodegenerative mutation in cytoplasmic dynein reveals 
novel regulation of motor activity 
Kassandra M. Ori-McKenney, Jing Xu, Steven P. Gross, Richard B. 
Vallee. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
52 
  
SMN-dependent U12 splicing defects cause synaptic dysfunction 
in a Drosophila model of spinal muscular atrophy 
Francesco Lotti, Wendy Imlach, Luciano Saieva, Erin Savner, Brian 
McCabe, Livio Pellizzoni. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
53 
  
An in vivo model system to investigate tau hyperphosphorylation 
in Alzheimer’s disease 
Giulia Povellato, Richard Tuxworth, Diane Hanger, Guy Tear. 
Presenter affiliation: King’s College London, London, United Kingdom. 
 
 
 
54 
  
 xv 
Electrophysiological characterisation of human embryonic stem 
cell and human 
induced pluripotent stem cell derived neurons. 
Clare A. Puddifoot, Andrea Serio, Bilada Bilican, Rickie Patani, David 
Wyllie, Giles Hardingham, Siddharthan Chandran. 
Presenter affiliation: The University of Edinburgh, Edinburgh, United 
Kingdom. 
 
 
 
 
 
 
55 
  
Antioxidants halt axonal degeneration and disability in X-
adrenoleukodystrophy 
Aurora Pujol, Jone Lopez-Erauskin, Stephane Fourcade, Agatha 
Schluter, Manuel Portero-Otin, Ekaterina Ilieva, Esther Dalfo, Isidre 
Ferrer. 
Presenter affiliation: ICREA-IDIBELL, Barcelona, Spain. 
 
 
 
 
 
56 
  
5’ regulatory regions of Machado-Joseph disease gene (ATXN3)—
Sequence analysis in patients and controls 
Conceição Bettencourt, Francisca Silva, Mafalda Raposo, Cristina 
Santos, Teresa Kay, João Vasconcelos, Patrícia Maciel, Jacóme 
Bruges-Armas, Manuela Lima. 
Presenter affiliation: University of the Azores, Ponta Delgada, Portugal. 
 
 
 
 
 
57 
  
The relationship between hippocampal and parahippocampal 
gray and white matter in controls, mild cognitive impairment, and 
Alzheimer’s disease 
Yasmine Y. Said, Ramez R. Mostafa, Beth Kuczynski. 
Presenter affiliation: Faculty of Medicine, Ain Shams University, Cairo, 
Egypt. 
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Small quinone-tryptophan molecules rescue Alzheimer's disease 
model 
Daniel Segal, Roni Scherzer-Attali, Ricardo Pellarin, Marino 
Convertino, Dorit Farafara, Tali Ben-Romano, Dorit Tudler, Anat 
Frydman-Marom, Nirit Egoz-Matia, Sivan Peled, Michal Levy-Sakin, 
Robert Vassar, Deborah E. Shalev, Dan Frenkel, Amedeo Caflisch, 
Ehud Gazit. 
Presenter affiliation: Tel-Aviv University, Tel Aviv, Israel. 
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Small molecule screen of yeast TDP-43 proteinopathy model 
identifies broadly protective compounds 
Dan Tardiff, Susan Lindquist. 
Presenter affiliation: Whitehead Institute for Biomedical Research, 
Cambridge, Massachusetts. 
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 xvi 
Human genetic modifiers of mutant Huntingtin aggregation 
Eva Teuling, Annika Bourgonje, Jelle de Boer, Karen Thijssen, Ellen A. 
Nollen. 
Presenter affiliation: University Medical Center Groningen, Groningen, 
Netherlands. 
 
 
 
 
61 
  
SH3 domains from a subset of BAR-proteins define a novel Ubl-
binding module and implicate parkin in synaptic ubiquitination 
Jean-Francois Trempe, Carol Xiuqing Chen, Karl Grenier, Peter S. 
McPherson, Kalle Gehring, Edward A. Fon. 
Presenter affiliation: Montreal Neurological Institute, McGill University, 
Montreal, Canada. 
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Complement 3/Aβ1-42 and factor H/Aβ1-42 in human 
cerebrospinal fluid correlate with Parkinson disease severity 
Yu Wang, Min Shi, Carmen Ginghina, Joshua Bradner, Aneeka 
Hancock, Jing Zhang. 
Presenter affiliation: University of Washington School of Medicine, 
Seattle, Washington; Tongji Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan, China. 
 
 
 
 
 
 
63 
  
Parkinson's mutations of LRRK2 regulate its autophosphorylation 
and activity 
Shuo Zhang, Zejuan Sheng, Claire Le Pichon, Sara Dominguez, 
Haitao Zhu. 
Presenter affiliation: Genentech, South San Francisco, California. 
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A novel splice variant of TRF2 retains rest in the cytoplasm and 
prevents excitotoxin-mediated dysregulation of neuronal genes 
Peisu Zhang, Michael J. Pazin, Rebecca C. Casaday, Mark M. 
Mattson. 
Presenter affiliation: NIA, National Institutes of Health, Baltimore, 
Maryland. 
 
 
 
 
 
65 
  
Leuven mutation of the alternative β-secretase cleavage site (β’-
site) of APP causes increased Aβ generation and is linked to 
Alzheimer’s disease 
Lujia Zhou, Nathalie Brouwers, Iryna Benilova, Annelies Vandersteen, 
Marc Mercken, Koen Van Laere, Philip Van Damme, David Demedts, 
Fred Van Leuven, Kristel Sleegers, Kerensa Broersen, Christine Van 
Broeckhoven, Rik Vandenberghe, Bart De Strooper. 
Presenter affiliation: VIB, Leuven, Belgium; KULeuven, Leuven, 
Belgium. 
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 xvii 
THURSDAY, December 2—7:30 PM 
 
 
SESSION 5 SUBMITTED ABSTRACTS 
 
Chairperson: S. Gandy, Mount Sinai School of Medicine, New York,  
  New York 
 
  
Genomic studies of ALS—Genome-wide association studies and 
beyond 
Bryan J. Traynor. 
Presenter affiliation: NIA, National Institutes of Health, Bethesda, 
Maryland. 
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New RNA binding proteins in ALS 
Aaron D. Gitler. 
Presenter affiliation: University of Philadelphia, Pennsylvania. 
 
 
68 
  
Experimental induction of cerebral Aβ deposition in transgenic 
rodents 
Lary C. Walker. 
Presenter affiliation: Emory University, Atlanta, Georgia. 
 
 
 
69 
  
A chemical screen identifies diverse pathways that spatially 
regulate axon degeneration 
Mark Chen, Janice Maloney, Jasi Atwal, Stephen Tam, Josh Kaminker, 
Zora Modrusan, Ryan J. Watts. 
Presenter affiliation: Genentech, Inc., South San Francisco, California. 
 
 
 
 
70 
  
Lack of complement receptors CR1 and CR2 or CR3 has distinct 
effects on amyloid pathology in mice 
Eva Czirr, Takeshi Fukuhara, Ramya Narasimhan, Markus Britschgi, 
Tony Wyss-Coray. 
Presenter affiliation: Stanford University, Palo Alto, California. 
 
 
 
 
71 
  
Regulation of ATXN1 phosphorylation at Ser 776 by PKA and 
PP2A—Avenues for SCA1 therapeutic development 
Shaojuan Lai, Sarita Lagalwar, Huda Y. Zoghbi, Harry T. Orr. 
Presenter affiliation: University of Minnesota, Minneapolis, Minnesota. 
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 xviii 
FRIDAY, December 3—9:00 AM 
 
 
SESSION 6 PROTEIN SORTING AND VPS10 PROTEINS IN 
NEURODEGENERATION 
 
Chairperson: V. Lee, University of Pennsylvania School of Medicine,  
 Philadelphia 
 
  
What can genetics teach us about treating Alzheimer's disease? 
Rudolph E. Tanzi. 
Presenter affiliation: Harvard Medical School/MGH, Charlestown, 
Massachusetts. 
 
 
 
73 
  
Diabetes-associated SorCS1 regulates Alzheimer’s Amyloid β 
metabolism—Evidence for involvement of SorL1 and the retromer 
complex 
Rachel F. Lane, Summer M. Raines, John W. Steele, Michelle E. 
Ehrlich, James A. Lah, Scott A. Small, Rudolph E. Tanzi, Alan D. Attie, 
Sam Gandy. 
Presenter affiliation: Mount Sinai School of Medicine, New York, New 
York; James P Peters Veterans Affairs Medical Center, New York, 
New York. 
 
 
 
 
 
 
 
 
74 
  
Retromer sorting in Alzheimer's disease—Pathways to 
pathogenesis 
Scott Small. 
Presenter affiliation: Columbia University, New York, New York. 
 
  
Determining the physiological roles of TDP-43 and its 
downstream targets. 
Philip C. Wong. 
Presenter affiliation: The Johns Hopkins University School of Medicine, 
Baltimore, Maryland. 
 
 
 
 
75 
  
Mechanisms underlying the paradoxical protective effect of the 
systemic amyloid precursor transthyretin on the localized  
amyloidosis Alzheimer's disease 
Joel Buxbaum. 
Presenter affiliation: The Scripps Research Institute, La Jolla, 
California. 
 
 
 
 
 xix 
Regulation of the fronto-temporal dementia protein, Progranulin, 
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 1 
BAPINEUZUMAB IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE 
 
Michael Grundman  
 
Janssen Alzheimer Immunotherapy, Clinical Development, South San 
Francisco, CA, 94080 
 
Preclinical studies in transgenic mice that produce excess Aβ have shown that 
antibodies directed against the N-terminal of Aβ can reduce amyloid deposits in 
the brain parenchyma and cerebral blood vessels. Previous Aβ immunotherapy 
studies in humans utilizing active immunization with the full length Aβ42 
peptide suggested potential clinical benefits. A one-year trial in immunized 
patients found that the subset of patients who were antibody responders showed 
improvement on a neuropsychological test battery. Additional follow-up of 
study subjects, approximately 4.5 years after immunization indicated that 
antibody responder patients showed less functional decline compared to placebo 
treated patients. Clinical testing of the full length Aβ42 peptide as a potential 
immunotherapy for AD was halted after meningoencephalitis developed in 6% 
of patients, a complication apparently due to a pro-inflammatory T-cell 
response against the Aβ peptide.  
 
Bapineuzumab, an antibody targeted against the N-terminus of Aβ, is a passive 
Aβ immunotherapy currently being tested for AD. One phase 2 study explored 
the long term safety and efficacy of bapineuzumab in 234 patients randomly 
assigned to intravenous (IV) bapineuzumab or placebo in four ascending dose 
cohorts. While no significant differences were observed in the primary efficacy 
analysis, exploratory analyses showed potential treatment differences on 
cognitive and functional endpoints in study completers and apolipoprotein E 
(ApoE) ε4 non-carriers. Reversible vasogenic edema (VE) was detected on 
brain MRI in approximately 10% of bapineuzumab-treated patients and was 
more frequent in higher dose groups and ApoE ε4 carriers. In another, smaller 
(N=28) phase 2 study that utilized [11C]PiB PET, bapineuzumab treated patients 
showed a reduction in [11C]PiB retention at week 78 compared to placebo 
suggesting a reduction in cortical fibrillar Aβ burden. The treatment difference 
in [11C]PiB retention tended to increase with longer treatment. A reduction in 
phospho-tau (p<0.05) was also observed in bapineuzumab vs. placebo treated 
patients when the CSF results in the two phase 2 studies were pooled.  
 
These biomarker and clinical findings provide support for current phase 3 
clinical trials with bapineuzumab. Different dose levels are being studied in 
carriers and non-carriers of ApoE4, and CSF, volumetric MRI, and amyloid 
imaging are employed to provide evidence of disease modification. Clinical 
efficacy measures combined with these biomarker results should help clarify the 
potential role of bapineuzumab as a disease modifying AD therapy.  
 
(Current address for Michael Grundman: Global R&D Partners, LLC, San 
Diego, CA 92130; email: michael@grndpartners.com) 
 2 
THERAPY PERSISTENCE WITH DISEASE-MODIFYING AD 
THERAPY – IMPACT ON NNT AND AD-FREE YEARS IN AN 
ASYMPTOMATIC POPULATION 
 
Nicolas M Furiak, Timothy M Klein, Megha Bansal, Robert W Klein  
 
Medical Decision Modeling Inc, Analytics, Indianapolis, IN, 46268 
 
Objective: To describe how therapy persistence and rates of adverse events 
(AEs) for a hypothetical disease-modifying Alzheimer’s disease (AD) 
therapy affect clinical outcomes when screening for AD neuropathology in 
a general asymptomatic population. 
Background: Assuming the future availability of treatments that attenuate 
underlying disease pathology in AD, and the availability of disease-
modifying therapies for AD, it will be important to evaluate the impact of 
AEs and therapy persistence on clinical outcomes from a societal 
perspective. A previously published AD screening model evaluating 
hypothetical therapy effectiveness and screening test characteristics 
demonstrated that a therapy increasing the time to clinical symptom onset 
by 50% significantly reduced incident dementia due to AD (DAD) cases. 
This study expanded the analysis to determine the impact of AEs and other 
discontinuation of therapy.  
Design/Methods: Probabilistic sensitivity analysis (PSA) was performed on 
AE rates and first-year discontinuation of therapy for other causes. Based 
on data for drugs to prevent other serious medical conditions such as breast 
cancer recurrence, the mean first-year non-specific discontinuation rates 
were set at 17% in months 1-6, and 5% in months 7-12. The means for 
treatment-specific AE discontinuation rates in the first year were 10% and 
2% per 5 years for remaining lifetime on therapy. The effectiveness of the 
hypothetical AD therapy was 50% and screening sensitivity and specificity 
were 0.87 and 0.78, respectively. PSA outcomes were summarized as 
acceptability curves showing the probability that an intervention reached 
thresholds of the number needed to treat (NNT) to achieve one AD-free 
year and avoid one case of DAD in 1000 cohorts of 1000 patients, each 
screened at age 70. 
Results: The mean number of patients treated in each PSA cohort was 236 
(range 191-275). Acceptability curves showed that with the screening and 
treatment characteristics, and discontinuation distribution specified there 
was a less than 1 in 1000 chance of the threshold for NNTs being greater 
than 5.5 patients to gain one AD-free year (median NNT 1.8) or 68.5 to 
avoid one DAD case. 
Conclusions: Given the hypothetical screening and treatment 
characteristics examined, the maximum NNTs of 5.5 patients to gain one 
AD free year and 68.5 to avoid one AD case, verify that screening for 
targeted AD treatment can be extremely valuable. This study is limited in 
that cost outcomes and specific AE characteristics are unknown but 
acceptable NNT thresholds will depend on them. 
 3 
RADIOPHARMACEUTICALS FOR DETECTION OF PATHOLOGICAL 
PROTEIN AGGREGATES IN NEURODEGENERATIVE DISEASES.  
 
Franz Hefti, Chris M Clark, Mark A Mintun, Michael J Pontecorvo, Daniel 
M Skovronsky  
 
Avid Radiopharmaceuticals, R&D, Philadelphia, PA, 19104 
 
Brain imaging provides a non-invasive tool for the detection of the defining 
pathological protein aggregates of neurodegenerative diseases, including Aβ 
and tau aggregates in Alzheimer’s disease (AD), α-synuclein aggregates in 
Parkinson’s disease (PD) and dementia with Lewy Bodies (DLB), and 
huntingtin aggregates in Huntington’s disease (HD). Radiopharmaceuticals 
selectively recognizing the individual aggregates are expected to be useful 
in the differential diagnosis of dementia and movement disorders, and for 
monitoring disease progression and the effects of disease-modifying drugs. 
Our efforts have focused on 18F-labeled radiopharmaceuticals for PET 
imaging, because of the high sensitivity and spatial resolution of the method 
and the possibility to make imaging diagnostics widely available.  
 
Our radiopharmaceutical for β-amyloid, florbetapir F 18 (18F-AV-45), was 
selected after synthesis of several hundred candidate ligands and the 
evaluation of a select number in phase I human trials under exploratory 
INDs. In vitro studies with postmortem human brain tissue established that 
florbetapir F 18 binds with high affinity (Kd = 3 nM) to β-amyloid, and 
Phase I human studies showed kinetic properties desired for a PET imaging 
agent. The Phase II studies showed clear separation of an AD population 
from healthy controls and, furthermore, detection of β-amyloid aggregation 
in 38% of individuals with mild cognitive impairment and 14% of normal 
elderly individuals. Control subjects with positive florbetapir-PET images 
performed worse on cognitive testing than those with negative images, 
indicating that β-amyloid aggregation is associated with identifiable 
changes in cognitive function. Subjects carrying the ApoEε4 genotype had 
higher florbetapir-PET signals than non-carriers. A Phase III study 
definitively demonstrated the ability of florbetapir-PET to identify β-
amyloid aggregation in the living brain. Correlations of both the visual and 
quantitative assessment of the florbetapir-PET image to β-amyloid 
aggregation found at autopsy were 0.78 and 0.75. Florbetapir had excellent 
reliability (test-retest variability <3%) and a short imaging time of 10 
minutes.  
 
PET imaging agents for tau and α-synuclein aggregates are currently at the 
discovery phase. Florbenazine F 18 (18F-AV-133), a radiopharmaceutical 
to quantify dopaminergic neuron degeneration is currently in clinical 
development. Updates of these programs will be presented at the meeting.  
 
The studies were supported by SBIR grants R43AG030869, R43AG032206, and a 
grant by the Michael J. Fox Foundation.  
 4 
PERSPECTIVES FOR THE FUTURE DEVELOPMENT OF 
NEUROPATHOLOGY: BIOMARKERS FOR ALZHEIMER’S DISEASE, 
PARKINSON’S DISEASE AND RELATED DISORDERS. 
 
John Q Trojanowski  
 
University of Pennsylvania, Pathology, Philadelphia, PA, 19104-4283 
 
Informative biomarkers for Alzheimer’s disease (AD), Parkinson’s disease 
(PD) and related disorders are urgently needed to improve the accuracy of 
early diagnosis and increase the efficiency of clinical trials of disease 
modifying therapies for these disorders. Progress of the Penn Biomarker 
Core in the AD Neuroimaging Initiative (ADNI) towards developing a 
pathological cerebrospinal fluid (CSF) and plasma biomarker signature for 
mild AD as well as a biomarker profile that predicts conversion of mild 
cognitive impairment (MCI) and/or normal control (NC) subjects to AD is 
described. ADNI exemplifies the global effort to standardize and validate 
biomarkers of AD. Further, the Parkinson Progression Marker Initiative 
(PPMI) is a newly launched effort to do the same for Parkinson’s disease 
(PD). Collaborative efforts to integrate data across diverse biomarker 
domains also is critical as exemplified by ADNI which has proposed a 
temporal ordering of changes in clinical measures, imaging data and 
chemical biomarkers that serve as mileposts and predictors of the 
conversion of NC to MCI as well as MCI to AD, and the progression of 
AD. For example, CSF studies by the ADNI Biomarker Core revealed a 
pathological CSF biomarker signature of AD defined by the combination of 
CSF levels of Aβ1-42 and tau that effectively delineates mild AD in the 
large multisite prospective clinical investigation conducted in ADNI. This 
signature appears to predict conversion from MCI to AD as well as 
cognitive decline in PD. Further, data fusion efforts across other ADNI 
Biomarker Cores generated a hypothetical model for the temporal ordering 
of AD biomarkers. This model suggests that Aβ amyloid biomarkers 
become abnormal first, followed by changes in neurodegenerative 
biomarkers (CSF tau, FDG-PET, MRI) and the onset of clinical symptoms. 
The timing of these changes varies between patients due to genetic and 
environmental factors that increase or decrease an individual's resilience in 
response to progressive accumulations of AD pathologies. Further studies in 
ADNI and PPMI will refine this model and render the biomarkers studied in 
ADNI more applicable to routine diagnosis and to clinical trials of disease 
modifying therapies, and PPMI work towards a similar goal for PD.  
Supported by grants from the NIH and the Michael J. Fox Foundation.  
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GENOME-WIDE ASSOCIATION STUDY OF FRONTOTEMPORAL 
LOBAR DEGENERATION WITH TDP-43 INCLUSIONS 
 
Vivianna Van Deerlin1, Patrick Sleiman3, Maria Martinez-Lage1, Alice 
Chen-Plotkin2,1, Li-San Wang1, Gerard Schellenberg1, Hakon Hakonarson3, 
John Q Trojanowski1, Virginia M Lee1, and the International Collaboration 
on FTLD1  
 
1University of Pennsylvania, Pathology and Laboratory Medicine, 
Philadelphia, PA, 19104, 2University of Pennsylvania, Neurology, 
Philadelphia, PA, 19104, 3Children's Hospital of Philadelphia, Center for 
Applied Genomics, Philadelphia, PA, 19104 
 
Frontotemporal lobar degeneration (FTLD) is the second most common 
cause of presenile dementia. The predominant neuropathology is FTLD 
with TAR DNA binding protein (TDP-43) inclusions (FTLD-TDP). FTLD 
is commonly familial and mutations in progranulin (GRN) are identified in 
~10-20%. A 45-site International Collaboration representing 11 countries 
was formed to collect FTLD-TDP cases to perform a genome-wide 
association study to identify susceptibility loci for FTLD-TDP. Over 600 
FTLD-TDP cases confirmed to have TDP-43 pathology and/or GRN 
mutations were collected. The GRN gene was sequenced in most cases. 515 
FTLD-TDP cases and 2,509 disease-free population controls were 
genotyped on Illumina HH550 or 610-Quad BeadChips. Cochran-Armitage 
trend test statistics were calculated at all markers following quality control 
filtering. Additional cases were used for replication by TaqMan SNP 
genotyping. To identify possible phenotype-associated differential 
expression TMEM106B gene expression was evaluated. Finally, the genetic 
and clinical characteristics of a subset of 97 cases with GRN mutations 
were assessed and compared to 453 cases of FTLD-TDP in which GRN 
mutations were excluded. FTLD-TDP associates with multiple SNPs 
mapping to a single linkage disequilibrium block on 7p21 that contains 
TMEM106B. Three SNPs retained genome-wide significance following 
Bonferroni correction (top SNP rs1990622, P = 1.08 x 10-11; odds ratio 
(OR) minor allele (C) 0.61, 95% CI 0.53-0.71). The association replicated 
in 89 FTLD-TDP cases (rs1990622; P = 2x10-4). Expression of 
TMEM106B was significantly correlated with TMEM106B genotype, with 
risk allele carriers showing higher expression. Age at onset, age at death, 
and presence of concomitant motor neuron disease differed between the 
GRN+ and GRN- groups. Variants in TMEM106B are implicated as a 
strong risk factor for FTLD-TDP, including in individuals with GRN 
mutations. TMEM106B variants may confer risk by increasing TMEM106B 
expression. GRN+ FTLD-TDP differs in key features from GRN- FTLD-
TDP.  
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CORRECTION OF SMN2 RNA SPLICING IN THE CNS AS A 
THERAPEUTIC STRATEGY FOR SPINAL MUSCULAR ATROPHY 
 
Yimin Hua1, Kentaro Sahashi1, Gene Hung2, Frank Rigo2, Marco Passini3, 
C Frank Bennett2, Adrian R Krainer1  
 
1Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY, 
11724, 2Isis Pharmaceuticals, 1896 Rutherford Rd, Carlsbad, CA, 92008, 
3Genzyme Corporation, 49 New York Ave, Framingham, MA, 01701 
 
Spinal Muscular Atrophy (SMA) is a genetic disease characterized by 
progressive degeneration of motor neurons in the anterior horn of the spinal 
cord, which in turn leads to severe muscle weakness and atrophy. SMA is 
caused by deletion or loss-of-function mutations in the Survival-of-motor-
neuron (SMN1) gene. The paralogous SMN2 gene, present in one or more 
copies in all SMA patients, attenuates the severity of SMA, but expresses 
only a low level of full-length SMN protein, due to alternative splicing that 
results in inefficient inclusion of exon 7. Increasing the extent of SMN2 
exon 7 inclusion to express more full-length, functional SMN protein in 
motor neurons is a promising approach to treat SMA. Previously, we 
identified an optimal 2’-O-(2-methoxyethyl) (MOE) 18mer antisense 
oligonucleotide (ASO) that targets an hnRNP A1 bipartite motif in an 
intron-7 splicing silencer (ISS-N1) and efficiently promotes SMN2 exon 7 
inclusion in liver and kidneys of transgenic mice after systemic 
administration. Because ASOs do not cross the blood-brain barrier, we 
explored direct delivery to the mouse central nervous system. Using a 
surgically implanted micro-osmotic pump, the ASO (dubbed ISIS-SMNRx) 
was delivered into cerebrospinal fluid through the right lateral ventricle in 
adult Smn-/- type-III SMA mice carrying a human SMN2 transgene. Dose-
response studies revealed that intracerebroventricular (ICV) infusion of the 
18mer ASO increased SMN2 exon 7 inclusion in spinal cord to ~90%, 
compared to ~10% in saline-treated mice. Western blotting and 
immunohistochemical analysis demonstrated a robust increase of the human 
transgenic SMN protein levels in spinal-cord motor neurons. We are using 
this and other ICV delivery methods, in combination with available SMA 
mouse models, to optimize the effectiveness of the ASO, characterize 
phenotypic improvement, and establish a time window for effective 
treatment. Our data show that ISIS-SMNRx is a promising drug candidate 
for SMA therapy. 
 7 
RNA MAPS IN HUMAN NEURODEGENERATIVE DISEASE. 
 
Robert B Darnell  
 
Rockefeller University/HHMI, Molecular Neuro-Oncology, New York, 
NY, 10065 
 
The brain has unique systems for regulating RNA metabolism, and these 
may play key roles in synaptic physiology and in degenerative human 
neurologic disease. Using studies of a neuron-specific RNA binding protein, 
Nova, as a platform, we have developed the HITS-CLIP method to identify 
protein-RNA interaction maps present in the living brain. Recently, we have 
expanded HITS-CLIP to the study of Argonaute-microRNA-mRNA ternary 
interactions, allowing us to precisely decode microRNA binding sites on a 
genome-wide scale. Overlaying these different sets of binding maps offers 
the potential to develop new insights into the dynamics of RNA regulation 
in the brain. At the same time, many robust protein-RNA and Ago-mRNA 
binding sites do not conform to current understanding of their function, 
offering a means for new discoveries of the role of RNA regulation in the 
normal and diseased brain. More recent insight into the role of these 
complexes in neurodegenerative disease has come from generating maps for 
RNA binding proteins implicated in motor neuron disease. 
 
Ule J et al. Nature, 444, 580-86, 2006;  
Licatalosi et al. Nature 456, 464-9, 2008. 
Chi et al., Nature, 460:479-86, 2009. 
Zhang et al., Science, 329:439-443, 2010 
 
This work was funded by the NIH and HHMI 
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DECIPHERING THE ROLE OF TDP-43 IN ALS/FTLD AND OTHER 
NEURODEGENERATIVE DISORDERS 
 
Robert H Baloh  
 
Washington University in St. Louis, Neurology, St. Louis, MO, 63110 
 
The identification of pathologic TDP-43 inclusions in amyotrophic lateral 
sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), followed 
by the discovery of dominantly inherited point mutations in both TDP-43 
and another RNA binding protein (FUS/TLS) in familial ALS, have been 
critical insights for defining the molecular pathways underlying these 
neurodegenerative disorders. 
 
TDP-43 transgenic animals recently generated by numerous labs appear 
promising, as they recapitulate some key features of ALS and FTLD 
pathology. Most develop progressive neurodegeneration with a strong 
threshold effect of transgene dosage. There is a notable predilection of 
TDP-43 toxicity for cortical layer V projection neurons and spinal motor 
neurons, mirroring at least in part the selective vulnerability seen in human 
ALS and FTLD. Although cytoplasmic TDP-43 inclusions are occasionally 
present in TDP-43 transgenic animals, surprisingly they are rare and do not 
appear to correlate with neurodegeneration. In contrast, other features 
observed in human pathologic samples are consistently found in TDP-43 
overexpressing animals – cleavage into C-terminal fragments, and depletion 
from the nucleus prior to cell death, however whether these are key players 
in the pathogenesis remains to be determined. These studies suggest that the 
molecular pathways underlying selective vulnerability to TDP-43 toxicity 
are shared between humans and mice, supporting that they will provide 
useful tools for both translational and mechanistic studies. 
 
While available transgenic rodent models recapitulate several features of 
ALS and FTLD, the biochemical basis of TDP-43 aggregation, the 
mechanism of how TDP-43 mutations lead to disease, and how 
neurodegeneration propagates through the vulnerable network remains 
enigmatic. In recent efforts to understand how TDP-43 alters its cellular 
localization in response to proteotoxic stress, we found that TDP-43 is 
sequestered into polyglutamine aggregates, which is mediated by a Q/N rich 
prion related domain in the C-terminal region of TDP-43. Interestingly, a 
similar domain was previously described in FUS/TLS. Ongoing efforts are 
aimed at exploring the importance of the prion related domain in TDP-43 
normal function and pathologic aggregation. 
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RNA BINDING PROTEINS AND FRONTOTEMPORAL LOBAR 
DEGENERATION 
 
Rocky Gao1, Tanya Monahiem1, Amar Kar1, Kazuo Fushimi1, Jane Y. Wu1 
1Department of Neurology, Lurie Cancer Center, Center for Genetic Medicine, 
Northwestern University School of Medicine, Chicago, IL  
 
Expression of genes critical for the formation and maintenance of the nervous 
system is controlled by complex networks of regulation at both transcriptional and 
post-transcriptional levels. RNA processing defects have been identified in a variety 
of neurodegenerative diseases and are emerging as important mechanisms 
underlying neurodegeneration. Genetic studies have uncovered both cis-acting 
mutations and trans-acting factors associated with neurodegenerative disorders, 
including tau-positive and ubiquitin-positive frontotemporal lobar degeneration 
(FTLD-tau and FTLD-u). Microtubule associated protein Tau is critical for 
microtubule stabilization and neuronal function. In the human brain, tau pre-mRNA 
splicing is regulated to maintain a delicate balance of different splicing isoforms, 
with the ratio of exon10-containing to exon 10-skipping transcripts as one. Aberrant 
tau exon 10 splicing has been found in a range of tauopathies, from progressive 
supranuclear palsy, cortical basal degeneration to FTLD-tau. Mutations in the 
human tau gene have been identified only in a small fraction of tauopathy cases with 
aberrant tau exon 10 splicing, suggesting the involvement of additional players in 
tauopathy. We have been systematically investigating molecular mechanisms 
regulating tau exon 10 alternative splicing. Our work has revealed both cis-acting 
splicing regulatory elements and trans-acting splicing regulators critical for tau exon 
10 splicing. Using multiple approaches, including UV cross-linking, expression 
cloning, yeast RNA-protein interaction screening and tandem-affinity purification 
coupled mass-spectrometry, we have identified a number of RNA binding proteins 
that regulate tau exon 10 alternative splicing. These tau exon 10 splicing regulators 
include both activators and suppressors that interact with either intronic or exonic 
splicing regulatory elements. Experiments are underway to examine the significance 
of these RNA binding proteins in the pathogenesis of FTLD-tau. On the other hand, 
numerous studies have implicated two multi-function RNA binding proteins, TAR 
DNA binding protein-43 (TDP-43) and fused in sarcoma (FUS) in the pathogenesis 
of FTLD-u, including FTLD-TDP and FTLD-FUS. To understand molecular 
pathogenesis of FTLD-TDP, we have begun to examine molecular, biochemical and 
functional characteristics of TDP-43 in cultured cells and in animal models. Using 
the powerful Drosophila system, we have built an animal model for FTLD-TDP and 
begun to address a number of important issues, including whether increased 
expression of wild type TDP-43 may lead to neurodegeneration and whether loss of 
function or gain of neurotoxic function are the primary pathogenic mechanism(s). 
Our transgenic flies expressing human TDP-43 recapitulate important 
neuropathological and clinical features of human TDP-43 proteinopathy, providing a 
powerful animal model for this group of devastating diseases. Our data indicate that 
simply increasing TDP-43 expression is sufficient to cause neurotoxicity in vivo, 
suggesting that aberrant regulation of TDP-43 expression or decreased clearance of 
TDP-43 may contribute to the pathogenesis of TDP-43 proteinopathy. Using this fly 
model, we have begun to systematically compare effects of wild type and mutant 
TDP-43 in neurons and to search for genetic modifiers of FTLD-TDP. Implications 
of our findings will be further discussed. Taken together, RNA binding proteins play 
important roles in the pathogenesis of FTLD, including both FLTD-tau and FTLD-u. 
Aberrant gene regulation by RNA binding proteins and RNA processing defects 
represent a general theme in neurogenerative diseases. 
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DEFINING THE ROLE OF DBR1 AS A POTENT MODIFIER OF TDP-
43 MEDIATED TOXICITY IN ALS 
 
Maria Armakola, Aaron D Gitler  
 
University of Pennsylvania, Department of Cell and Develpomental 
Biology, Philadelphia, PA, 19104 
 
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar 
Degeneration with ubiquitin positive inclusions (FTLD-U) are a group of 
neurodegenerative disorders characterized by the presence of TDP-43 
positive inclusions in the cytoplasm of degenerating neurons in the brain. 
These disorders are collectively known as TDP-43 proteinopathies. 
Mutations in the TDP-43 gene (TARDBP) have been found to be associated 
with familial cases of ALS and FTLD-U. TDP-43 is a ubiquitously 
expressed DNA/RNA binding protein that regulates gene expression in 
multiple levels, including transcription, RNA splicing and mRNA 
translation. The mechanism whereby TDP-43 contributes to pathogenesis is 
unknown. TDP-43 is normally a nuclear protein but pathological inclusions 
contain cytoplasmic TDP-43 suggesting that altered subcellular localization 
of the protein may be important for disease pathogenesis. Despite the 
central role of TDP-43 in the pathogenesis of ALS and FTLD-U, currently 
there is no TDP-43 directed therapy for the disease. To gain insight into 
disease pathogenesis we performed an unbiased screen to define modifiers 
of TDP-43 mediated toxicity using a yeast TDP-43 proteinopathy model. 
We identified a deletion of the DBR1 gene as a potent suppressor of TDP-
43 toxicity in yeast. DBR1 encodes an RNA debranching enzyme that 
cleaves the 2'-5' phosphodiester bonds of the lariat introns formed during 
pre-mRNA splicing. Importantly, DBR1 is conserved from yeast to man. In 
our preliminary studies we found that deleting Dbr1 in yeast completely 
suppresses TDP-43 toxicity and that this rescue is specific to the loss of its 
debranching enzymatic activity, raising the intriguing possibility that this 
activity could be a promising therapeutic target. We are continuing to 
characterize the TDP-43/DBR1 interaction in mammalian cells and 
Drosophila. For this purpose we have developed a mammalian cell toxicity 
model of TDP-43 proteinopathy that will serve as a platform to determine 
the mechanism through which downregulation of DBR1 rescues TDP-43 
mediated toxicity. To determine if DBR1 is a modulator of TDP-43 toxicity 
in vivo we are using a Drosophila model of TDP-43 proteinopathy. These 
studies will provide the foundation for determining if the enzymatic activity 
of Dbr1 is a promising therapeutic target for drug design. 
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DISEASE-LINKED MUTANT HUMAN TDP-43 ACCUMULATED TO 
MODERATE LEVELS CAUSES LATE ONSET MOTOR NEURON 
DEFICITS IN MICE 
 
Eveline S Arnold1,2,4, Michael Hefferan3, Shuo-Chien Ling1,2, Clotilde 
Lagier-Tourenne1,2, Magdalini Polymenidou1,2, Dara Ditsworth1,2, Martin 
Marsala3, Don W Cleveland1,2  
 
1UC San Diego, Cellular and Molecular Medicine, La Jolla, CA, 92093, 
2Ludwig Institute for Cancer Research, Laboratory for Cell Biology, La 
Jolla, CA, 92093, 3UC San Diego, Department of Anesthesiology, La Jolla, 
CA, 92093, 4UC San Diego, Biomedical Sciences Graduate Program, La 
Jolla, CA, 92093 
 
In 2006, TAR DNA Binding Protein (TDP-43) was identified as the major 
protein component of ubiquitinated inclusions found the overlapping 
pathology in both frontotemporal lobar degeneration with ubiquitinated 
inclusions (FTLD-U) and Amyotrophic Lateral Sclerosis (ALS). Since 
2008, thirty-eight mutations have been reported in familial and sporadic 
cases of ALS, suggesting that dysfunction of TDP-43 presents a common 
pathway of neurodegeneration linking familial ALS (accounting for 10% of 
all ALS cases) and sporadic ALS. To characterize the normal biological 
function of TDP-43 and how mutations in it produce disease, we generated 
multiple transgenic lines of mice expressing wild-type human TDP-43 as 
well as two disease-linked mutations, Q331K and M337V, which express 
myc-tagged human TDP-43 cDNA under the control of the mouse prion 
promoter (MoPrP). Three lines each of wild-type TDP-43, Q331K and 
M337V-expressing transgenic mice have been established. The highest 
expressing lines produce protein levels equal to the endogenous protein in 
the brain and spinal cord. Furthermore, biochemical, behavioral and 
pathological characterization of aging cohorts of wild-type, Q331K and 
M337V-expressing transgenic mice reveal an age-dependent development 
in mutant mice of markers of inflammation (astrogliosis and microgliosis) 
in the spinal cord accompanied by increased muscle activity identified by 
electromyography and a reduced number of motor axons. 
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A NON-ACTIVE SITE, FUNCTION-BLOCKING ANTI-BACE1 
ANTIBODY THAT SIGNIFICANTLY REDUCES ABETA 
PRODUCTION IN VIVO 
 
Jasi Atwal1, Yongmei Chen1, Cecilia Chiu1, Scott Stawicki1, Chris Heise1, 
Yichin Liu1, Yanmei Lu1, Deborah Mortensen2, Kimberly Scearce-Levie1, 
Yingnan Zhang1, Bob Lazarus1, Weiru Wang1, Yan Wu1, Marc Tessier-
Lavigne1, Ryan J Watts1  
 
1Genentech, Research, South San Francisco, CA, 94080, 2Genentech, 
Developmental Sciences, South San Francisco, CA, 94080 
 
Reducing Abeta production by direct inhibition of amyloid precursor 
protein (APP) secretases has been a major therapeutic strategy for treating 
Alzheimer’s Disease. Development of small molecule inhibitors of beta-
secretase (BACE1) or gamma-secretase has been met with many challenges. 
Progress has been limited by the difficulty of generating inhibitors that are 
truly selective and blood-brain barrier penetrant, thus raising concerns about 
both safety and efficacy. Here, we describe the characterization of a high 
affinity, phage-derived human antibody selectively targeting BACE1 (anti-
BACE1). Anti-BACE1 inhibits activity of mouse and human BACE1 in 
APP enzymatic cleavage assays. Furthermore, anti-BACE1 inhibits 
endogenous BACE1 and Abeta production in human APP expressing cell 
lines and in primary neuron cultures. The activity of anti-BACE1 is highly 
selective, as shown by the complete lack of inhibitory effects on either 
CathepsinD or BACE2 activity, and by pharmacokinetic studies in wild-
type versus BACE1 knockout mice. Systemic dosing of anti-BACE1 in vivo 
shows a strong reduction in peripheral Abeta levels, and a modest but 
significant reduction of CNS Abeta levels, correlating with anti-BACE1 
antibody levels detected in brain. Finally, crystallography and competitive 
binding studies indicate that the mode of action for the anti-BACE1 
antibody is non-competitive through binding to an exosite on BACE1. 
These data provide evidence that BACE1 may be therapeutically targeted in 
a highly selective manner via a passive immunological approach. 
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PROCASPASE-ACTIVATING COMPOUND 1 INDUCES A CASPASE-
3-DEPENDENT CELL DEATH IN CEREBELLAR GRANULE 
NEURONS 
 
Gulzeb Aziz*1, Øyvind W. Akselsen*2, Trond V. Hansen2, Ragnhild E. 
Paulsen1  
 
1Department of Pharmaceutical Biosciences, School of Pharmacy, 
University of Oslo, OSLO, N-0316 OSLO, Norway, 2Department of 
Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, OSLO, 
N-0316 OSLO, Norway 
  
Procaspase-activating compound 1, PAC-1, has been introduced as a direct 
activator of procaspase-3 and suggested as a therapeutic agent against 
cancer. Its activation of procaspase-3 is dependent on the chelation of zinc. 
We have tested PAC-1 and an analogue of PAC-1 as zinc chelators in vitro 
as well as their ability to activate caspase-3 and induce cell death in chicken 
cerebellar granule neuron cultures. These neurons are non-dividing, primary 
cells with normal caspase-3. The results reported herein show that PAC-1 
chelates zinc, activates procaspase-3, and leads to caspase-3-dependent cell 
death in neurons, as the specific caspase-3-inhibitor Ac-DEVD-cmk 
inhibited both the caspase-3 activity and cell death. Thus, chicken cerebellar 
granule neurons is a suitable model to study mechanisms of interference 
with apoptosis of PAC-1 and similar compounds. Furthermore, the present 
study also raises concern about potential neurotoxicity of PAC-1 if used in 
cancer therapy. 
 
Key words: apoptosis, caspase-3, PAC-1, procaspase 
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VARIATION IN THE AGE AT ONSET OF MACHADO-JOSEPH 
DISEASE: THE INFLUENCE OF THE APOE POLYMORPHISM 
 
Conceição Bettencourt1,2,3, Mafalda Raposo1, Cristina Santos4, Teresa Kay5, 
João Vasconcelos6, Patrícia Maciel7, Manuela Lima1,2  
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of Porto, Molecular and Cellular Biology Institute (IBMC), Porto, 4150-
180, Portugal, 3University Complutense of Madrid, Laboratorio de 
Diagnostico Molecular del Banco de Tejidos para Investigaciones 
Neurológicas (BTIN), Madrid, 28040, Spain, 4Autonomous University of 
Barcelona, Unitat Antropologia Biològica, Barcelona, 08193, Spain, 
5Hospital of D. Estefania, Department of Clinical Genetics, Lisbon, 1169-
045 , Portugal, 6Hospital of Divino Espirito Santo, Department of 
Neurology, Ponta Delgada, 9500, Portugal, 7University of Minho, Life and 
Health Sciences Research Institute (ICVS), School of Health Sciences, 
Braga, 4710-057 , Portugal 
 
Machado-Joseph disease (MJD) is an autosomal dominant 
neurodegenerative disorder of late onset (mean of 40.2 years), caused by a 
CAG expansion in the coding region of the ATXN3 gene (14q32.1). 
Variation in age at onset is partially explained by the size of the CAG repeat 
tract in the expanded alleles. The remaining variation in onset should be the 
product of other factors, namely modifier genes. APOE genotypes have 
been described as a possible phenotype modifier factor in different 
neuropathological settings, namely Parkinson’s disease and Huntington’s 
disease. The main goal of this work was to investigate the putative 
modulating effect of APOE polymorphism on the age at onset of MJD. A 
series of 57 Azorean MJD patients was analyzed. Cases with the ε2/ε3 
genotype presented an earlier mean age at onset than patients with the ε3/ε3 
and the ε3/ε4 genotypes. When adding, in a generalized estimating equation 
model, the presence/absence of APOE ε2 allele to the number of CAG 
repeats, the explanation of the onset variance significantly increased from 
68.2% to 71.6%. Furthermore, the presence of the APOE ε2 significantly 
decreases the age at onset by nearly 7 years. These preliminary results 
suggest that the APOE polymorphism may play a role as a modifier of the 
MJD phenotype. 
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MODELLING MOTOR NEURON DISEASE USING INDUCED 
PLURIPOTENT STEM CELLS 
 
Bilada Bilican1,2,3, Andrea Serio1,2,3, Gareth J. Sullivan1,2,3, Agnes 
Nishimura6, In-Hyun Park8, Judy Fletcher1,2,3, Clare Puddifoot4, David 
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Wilmut1,2, Tom Maniatis5, Chris E. Shaw6, Siddharthan Chandran1,2,3 
 
1University of Edinburgh, Euan MacDonald Centre for Motor Neuron 
Disease Research, UK, 2University of Edinburgh, Centre for 
Neuroregeneration, UK, 3University of Edinburgh, MRC Centre for 
Regenerative Medicine, UK, 4University of Edinburgh, Centre for 
Integrative Physiology, UK, 5Columbia University Medical Center, 
Department of Biochemistry and Molecular Biophysics, New York, NY, 
6Institute of Psychiatry, King’s College London, MRC Centre for 
Neurodegeneration Research, UK, 7Harvard Medical School, Children's 
Hospital Boston, MA, 8Yale School of Medicine, Department of Genetics, 
New Haven, CT. 
 
The mechanistic basis underlying progressive and selective degeneration of 
motor neurons in motor neuron disease (MND) is poorly understood. The 
discovery that TDP-43 is the major protein within ubiquitinated cytoplasmic 
inclusions, the hallmark pathology in 90% of MND cases and the recent 
identification of causative TDP-43 mutations in 1-4% of familial and 
sporadic cases highlights the need to develop experimental models to 
address the consequences of mutant TDP-43. Recent discoveries in 
reprogramming and resulting derivation of human induced pluripotent stem 
cells (iPS) permit human-based cellular models to study the consequences 
of disease causing mutations. In order to establish a platform for in vitro 
disease modeling we sought in this study to first generate iPS lines from 
TDP43 M337V mutation carrying and control individuals and next optimize 
differentiation protocols for motor neurons. Generation of iPS cells from 
adult human fibroblasts was undertaken by viral transduction of Oct4, Sox2, 
Klf4 and Myc. Resulting clones were characterised and validated by 
standard criteria including expression of pluripotency markers, bisulphite 
sequencing and teratoma formation. Neural conversion of iPS cells was 
achieved by dual inhibition of SMAD-signalling and generation of 
functional MNs was assessed by IHC, PCR, electrophysiology and 
myoblast co-cultures following patterning with Shh and RA. TDP-43 
mutant and control iPS lines both gave rise to HB9/ChAT (+) mature motor 
neurons that were electrophysiologically active and formed neuromuscular 
junctions in myoblast co-culture. Our results establish an in vitro human 
experimental platform to begin to address cellular autonomy of MN 
degeneration and the role of TDP-43. 
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REGULATION OF TDP-43 AGGREGATION BY PHOSPHORYLATION 
AND AUTOPHAGY PATHWAY 
 
Owen A Brady, Peter S Meng, Yanqiu Zheng, Yuxin Mao, Fenghua Hu  
 
Cornell University, Weill Institute for Cell and Molecular Biology, Ithaca , 
NY, 14853 
 
TDP-43 proteinopathy has been linked to several neurodegenerative 
diseases, including Frontotemporal Lobar Degeneration with ubiquitin 
positive inclusions (FTLD-U) and Amyotrophic Lateral Sclerosis (ALS). 
Phosphorylated and ubiquitinated TDP-43 C-terminal fragments have been 
found in cytoplasmic inclusions in FTLD-U and ALS patients. However, 
the factors and pathways that regulate TDP-43 aggregation are still not 
clear. We found that the C-terminal 15kDa fragment of TDP-43 is sufficient 
to induce aggregation but the aggregation phenotype is modified by 
additional sequences. Aggregation is accompanied by phosphorylation at 
serine residues 409/410. Mutation of 409/410 to phosphomimetic aspartic 
acid residues significantly reduces aggregation and ubiquitination. 
Inhibition of autophagy dramatically increases TDP-43 aggregation. 
Furthermore, TDP-43 aggregates colocalize with markers of autophagy and 
the autophagy adaptor protein SQSTM1/p62. Overexpression of 
SQSTM1/p62 reduces TDP-43 aggregation. These studies suggest that 
aggregation of TDP-43 is regulated by phosphorylation events and the 
autophagy pathway. 
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PINK1 DEFICIENCY RESULTS IN ABNORMAL DOPAMINE 
HOMEOSTASIS AND AFFECTS INNATE IMMUNE AND CELL 
SURVIVAL SIGNALING 
 
Ravi S Akundi1, Zhenyu Huang1, Joshua Eason1, Jignesh D Pandya2, 
Wayne A Cass1, Lianteng Zhi1, Patrick G Sullivan2, Hansruedi Büeler1  
 
1University of Kentucky, Anatomy and Neurobiology, Lexington, KY, 
40536, 2University of Kentucky, Spinal Cord and Brain Injury Research 
Center, Lexington, KY, 40536 
 
Mutations in the mitochondrial kinase PINK1 are linked to recessive 
familial Parkinson’s disease (PD) with onset in the third to fourth decade of 
life. In cultured cells PINK1 and Parkin (another recessive PD gene) 
maintain a healthy pool of mitochondria by promoting the degradation of 
functionally impaired mitochondria through autophagy. To further study 
how the loss of PINK1 affects mitochondrial function and other PD-
relevant pathways in vivo, we generated and characterized a new line of 
PINK1-deficient (PINK1-/-) mice. Compared to wildtype mice, Ficoll-
gradient purified mitochondria from the brain of PINK1-/- mice displayed 
enhanced Ca2+-induced permeability transition (rescued by cyclosporine A). 
Moreover, phosphorylated c-Jun accumulated in a subpopulation of 
dopaminergic neurons in young PINK1-/- mice, and PINK1-deficient mice 
aged 6 months and older showed reduced levels of dopamine associated 
with increased dopamine turnover in the striatum. In response to a 
peripheral inflammatory stimulus PINK1-/- mice had increased levels of 
select cytokines in the striatum. Quantitative transcriptional profiling 
showed abnormal striatal expression of genes that regulate innate immunity 
and apoptosis, mitogen-activated protein kinase signaling as well as axonal 
sprouting and regeneration. PINK1-/- embryonic fibroblasts showed reduced 
basal and inflammatory cytokine-induced NF-κB signaling and were 
severely impaired in the activation of the survival kinase Akt, which is 
required for the protection of dopamine neurons in various animal models 
of PD. Collectively, these results show multiple abnormalities in the 
nigrostriatal system of PINK1-/- mice and cells and implicate aberrant innate 
immune signaling and impaired activation of cell survival pathways as 
novel mechanisms involved in the pathogenesis of recessive Parkinsonism. 
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Parkinson’s Disease (PD) is the second-most common neurodegenerative 
disease in the United States, and is increasing in prevalence. PD is 
characterized by the loss of neurons in the nigrostriatal pathway and 
dyskinesis, as well as non-motor effects, such as cognitive deficits, 
dementia, and mortality. Sporadic idiopathic PD is thought to develop 
through interactions between age, genetics, and environment, but exact 
mechanisms are unknown. Loss of function mutations in Parkin and 
UCHL1 associated with familial forms of PD suggest that perturbations in 
the ubiquitin-proteasome system may contribute to idiopathic PD. The 
presence of reactive cysteines on E1 activating enzyme, which is at the apex 
of the ubiquitination cascade, may render it susceptible to inhibition through 
covalent modification by environmental agents that generate electrophiles. 
Because of its ability to modify proteins on cysteines, we hypothesized that 
N,N-diethyldithiocarbamate (DEDC), a member of the 
dialkylthiocarbamate family of pesticides, could covalently modify the E1 
activating enzyme, resulting in compromised protein processing and 
nigrostriatal toxicity. To test our hypothesis, rats were exposed to 0.3 
mmol/kg/day of DEDC for 8 weeks, and E1 function was assessed by 
measuring activated E1 and total ubiquinated protein levels, both of which 
were significantly decreased in brains of DEDC-treated rats as compared to 
non-treated controls. Covalent modifications of E1 assessed by shotgun 
LC/MS/MS of peptide digests revealed formation of an S-
ethylaminocarbonyl adduct on a single cysteine residue (Cys234). 
Incubation of recombinant human E1 with ethyl isocyanate to form the S-
ethylaminocarbonyl adduct significantly decreased E1 activity compared to 
non-treated E1, suggesting that this covalent modification is responsible for 
the inhibition observed in vivo. Total TH protein was significantly 
decreased in brains of DEDC-treated rats as compared to controls. There 
was no difference in dopamine levels, which may have been maintained 
through increased activation of TH via phosphorylation. Additionally, 
elevated levels of α-synuclein and phosphorylated tau proteins were 
observed in the DEDC-treated rats. These data suggest that inhibition of E1 
by covalent modification at Cys234 by environmental agents can contribute 
to the development of PD particularly in individuals with SNPs in the SNCA 
and MAPT genes identified by genome wide analysis to increase the risk of 
sporadic PD. 
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The role of a small TGF-β-induced TIAF1 in contributing to the 
pathogenesis of Alzheimer’s disease (AD) was investigated. TIAF1 
interacts with Smad4 in vivo, and blocks Smad-dependent promoter 
activation when overexpressed. Knockdown of TIAF1 by small interfering 
RNA resulted in spontaneous accumulation of Smad proteins in the nucleus 
and activation of the promoter governed by the Smad complex. TGF-β may 
rapidly induce TIAF1 self-aggregation that leads to apoptosis in a caspase-
dependent manner in vitro. By filter retardation assay, we determined that 
TIAF1 aggregates are abundant (~55%) in the hippocampi of nondemented 
humans and AD patients. Total TIAF1-positive samples containing Aβ 
aggregates are 17% and 48%, respectively, in the nondemented and AD 
groups, suggesting that TIAF1 aggregation occurs preceding formation of 
Aβ plaques. TIAF1 aggregates might provide protection for Aβ plaque 
formation as determined in transgenic mouse models. TGF-β1 induces 
TIAF1 self-aggregation in a type II TGF-β receptor-independent manner in 
cells, and Smad4 interrupts the aggregation. TIAF1 physically binds 
Thr668-phosphorylated amyloid precursor protein (APP). TGF-β1 reduces 
the binding that allows TIAF1 aggregation and APP de-phosphorylation and 
fragmentation, Aβ production, and apoptosis. Together, TIAF1 self-
aggregation occurs in nondemented humans and may facilitate the 
formation of Aβ plaques during progression toward AD. 
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Frontotemporal dementia (FTD) is the most common cause of early-onset 
dementia, and is characterized by behavioral and language dysfunction that 
may be accompanied by motor neuron disease. The neuropathological 
hallmark of FTD is the selective degeneration of the frontal and temporal 
lobes with the presence of intracellular protein aggregates, containing either 
the microtubule-associated protein tau (FTD-TAU) or the RNA binding 
protein TDP-43 (FTD-TDP). Familial FTD (accounting for about 50% of 
the cases) has been linked to mutations in several genes, including tau 
(MAPT), progranulin (GRN), valosin-containing protein (VCP) and 
charged multivesicular body protein 2B (CHMP2B). However, the cause of 
the disease in the majority of familial cases and in the common sporadic 
forms remains unknown. Exome capture (the massively parallel sequencing 
of enriched target exon sequences) allows an unbiased investigation of the 
complete protein-coding regions in the genome. In order to identify the 
causal gene underlying the disease in a FTD-TDP family (negative for tau 
and GRN mutations and showing an autosomal dominant pattern of disease 
inheritance), we captured and sequenced the exomes of 3 affected and 1 
unaffected siblings. We achieved a mean coverage of 91X and sufficient 
depth (8X) to call variants at ~ 92% of each targeted exome. We identified 
an average of ~ 25500 variant (SNPs, indels or splice-site mutations) per 
sample, of which 1269 were common to the affected but absent in the 
unaffected siblings. Filtering against public SNP databases identified 23 
novel variants. We were able to reduce the number of candidate genes to 8-
9 by direct sequencing of the variants in an additional unaffected sibling. 
We are currently sequencing the variants in hundreds of unrelated controls 
to further narrow down the number of candidate genes. Exome sequencing 
of a small number of related affected and unaffected individuals in a 
pedigree, combined with sequencing of unrelated controls and functional 
studies of the identified variants, promises therefore to be a powerful, 
efficient strategy for identifying candidate genes underlying familial 
disorders, even in complex, heterogeneous diseases.  
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Progranulin (PGRN) is a secreted protein that has been implicated in 
multiple physiological and disease processes. Autosomal dominant 
mutations within the progranulin gene (GRN) cause frontotemporal 
dementia with tau negative ubiquitin positive neuronal inclusions (FTLD-
U). Almost all the mutations lead to PGRN haploinsufficiency. TAR DNA-
binding protein 43 (TDP-43), encoded by the TARDBP gene, has been 
identified as the major pathological protein of FTLD-U and the presence of 
C-terminal TDP-43 in the ubiquitin inclusions is characteristic of GRN-
mediated FTLD-U. PGRN is widely expressed by nerve cells, including 
many that appear unaffected in FTLD-U. Little is known of the mechanisms 
by which reduced PGRN expression leads ultimately to neuronal 
degeneration, and a fuller understanding the function of PGRN in neuronal 
cells should provide insight into this issue. Using motor neuronal cell lines 
with different levels of PGRN expression we have investigated the ability of 
PGRN to regulate neurite outgrowth, inhibit apoptosis, and regulate 
translocation of TDP-43 following apoptotic challenge. PGRN has a strong 
cytoprotective action, modulates the cytoskeletal architecture and promotes 
neurite-like outgrowth in vitro. We then employed zebrafish to study the 
role of PGRN in neurons in vivo. The zebrafish possesses four distinct GRN 
genes of which zfPGRN-A is the true orthologue of the single human gene. 
ZfPGRN-A is expressed in embryonic zebrafish neuronal tissue, including 
the primary motor neurons, which can be readily visualized in whole mount 
embryos. Ectopic over-expression of zfPGRN-A resulted in increased 
branching of the Caudal Primary (CaP) motor neurons by 48hrs. When 
ZfPGRN-A was knocked down using a morpholino antisense strategy we 
observed truncation of CaP motor neurons with premature branching and an 
impaired swimming response. Co-expression of zfPGRN-A mRNA rescued 
both the truncation and swimming defect. Two independent morpholinos 
were employed to exclude non-specific effects, and the reduction in 
zfPGRN-A protein levels was confirmed by Western blot analysis. The 
truncation and early branching phenotype observed by knockdown of 
zfPGRN-A are strikingly similar to those reported following morpholino 
knockdown of Survival of Motor Neuron-1 smn1 in zebrafish embryos, 
mutations of which cause Spinal Muscular Atrophy in humans. We 
therefore challenged smn1 knockdown embryos with zfPGRN-A mRNA 
and found a significant reversal of the smn1 knockdown phenotype. We 
conclude that PGRN expression is capable of modulating neuron survival, 
branching and development in vitro and in vivo. 
 22 
RANBP2-MEDICATED NEUROPROTECTION CAUSES THE 
MODULATION OF PROTEIN-LIPID HOMEOSTASIS OF 
FUNCTIONALLY DIVERSE BUT LINKED PATHWAYS IN 
RESPONSE TO OXIDATIVE STRESS. 
 
Kyoung-in Cho, Paulo A Ferreira  
 
Duke University Medical Center, Department of Ophthalmology, Durham, 
NC, 27710 
 
Oxidative stress is associated with a plethora of human diseases, aging 
manifestations and metabolic deficits. Light-elicited oxidative stress is a 
deleterious risk factor linked to retinal dystrophies, such as age-related 
macular degeneration (AMD) and retinitis pigmentosa (RP), which occur 
owing to the selective degeneration of photoreceptor neurons. The 
identification and characterization of factors and processes that suppress the 
deleterious effects of oxidative stress may provide insight into mechanisms 
of neuroprotection and uncover novel therapeutic targets by which the 
clinical manifestations of various diseases and aging can be modulated. The 
purpose of our work is to explore the molecular effects of insufficiency of 
RAN-binding protein-2 (RANBP2) in protecting photoreceptors and the 
supporting tissue, the retinal pigment epithelium (RPE), from degeneration 
induced by light-elicited oxidative stress. We contrasted the molecular, 
biochemical, cellular and subcellular phenotypes of photoreceptors and RPE 
of inbred wild-type mice and RANBP2-haploinsufficient mice in the 
absence or presence of light-elicited oxidative stress. We found that 
membrane biogenesis and the expression levels of a subset of functionally 
diverse and binding partners of RANBP2 – such as RAN GTPase, ubc9, 
subunits of the 26S proteasome and a set of orphan nuclear receptors – are 
differentially modulated by RANBP2 haploinsufficiency and oxidative 
stress in the retina. The effects of oxidative stress are also accompanied in 
RANBP2-haploinsufficient mice by a decrease in the levels of ubiquitylated 
proteins, thus supporting that insufficiency of RANBP2 relieves its 
suppression on the activity of 26S proteasome in the presence of oxidative 
stress. Strikingly, the formation of lipid deposits induced by oxidative stress 
in the RPE – a hallmark of many neurodegenerative diseases and aging – is 
strongly suppressed by RANBP2 haploinsufficiency. Conversely to the 
retina, the expression levels of most RANBP2-binding partners are not 
affected in the RPE. Thus, the data indicate that insufficiency of RANBP2 
results in the cell-type-dependent downregulation of protein and lipid 
homeostasis, acting on functionally interconnected pathways in response to 
oxidative stress. These results provide a rationale for the neuroprotection 
from light damage of photosensory neurons by RANBP2 insufficiency and 
for the identification of novel therapeutic targets and approaches promoting 
neuroprotection. 
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Amyotrophic lateral sclerosis (ALS) is characterized by progressive 
dysfunction and degeneration of motor neurons in the central nervous 
system (CNS). In the absence of effective drug treatments for ALS, stem-
cell treatment has emerged as a candidate therapy for this disease. Here, we 
investigated the effects of neural induction on the innate therapeutic 
potential of mesenchymal stem cells (MSCs). MSCs were neurally induced 
by transduction with the proneural transcription factor. MSCs transduced 
with proneural gene (Neu-MSCs) were next tested in mice carrying a high 
copy-number of the human mutant SOD1G93A transgene. After systemic 
injection, Neu-MSCs migrated to the spinal cord, where they protected 
ventral motor neurons but rarely became terminally differentiated neurons. 
Notably, Neu-MSCs, but not unprocessed MSCs, delayed disease onset if 
transplanted during pre-onset stages. If transplanted at onset ages, a single 
treatment with Neu-MSCs was sufficient to enhance motor functions during 
the symptomatic period (15–17 weeks). By contrast, unprocessed MSCs 
required repeated transplantation to achieve similar levels of motor function 
improvement. Our data indicate that systemically transplanted Neu-MSCs 
can migrate to the CNS and exert beneficial effects on host neural cells 
through paracrine effects for an extended period of time. Our findings 
strongly suggest a potential benefit of neural induction of MSCs for the 
long-term treatment of ALS. 
 24 
BIOCHEMICAL CHARACTERIZATION OF FULL-LENGTH HUMAN 
RECOMBINANT LRRK1 AND LRRK2 
 
Laura Civiero1, Elisa Greggio1, Jean-Marc Taymans2, Alexandra Beilina3, 
Mark R Cookson3, Veerle Baekelandt2, Luigi Bubacco1  
 
1University of Padova, Department of Biology, Padova, 35131, Italy, 
2KULeuven, Laboratory for Neurobiology and Gene Therapy, Leuven, 
3000, Belgium, 3NIH, Laboratory of Neurogenetics, Bethesda, MD, 20982 
 
Leucine-rich repeat kinase 1 and 2 (LRRK1 and LRRK2) are large, 
complex multidomain proteins containing kinase and GTPase enzymatic 
activities and multiple protein-protein interaction domains. Rare mutations 
in LRRK2 are linked to autosomal dominant forms of Parkinson’s disease 
(PD) and some common LRRK2 variants also increase the risk of PD in 
some populations. In contrast, LRRK1 mutations have not been reported yet 
and we have previously shown that pathological mutations in LRRK2 are 
more toxic than the equivalent mutations in LRRK1. Because LRRK2 is a 
kinase, this has led to the suggestion that kinase inhibitors might be a novel 
therapeutic opportunity for PD. 
 
Starting from the idea that LRRK2 but not LRRK1 is associated with PD, 
we decided to characterize the two proteins in parallel to single out LRRK2 
specific properties. At present, most biochemical studies have been 
performed using suspensions of protein bound to affinity resin. Reports on 
recombinant LRRK2 in solution refer to truncated fragments, often also 
containing large affinity tags (i.e. GST). Here, we produced highly pure 
recombinant LRRK1 and LRRK2 soluble proteins with a small affinity tag. 
Using a lentiviral expression vector, we have been able to express 3xFLAG 
tagged full-length LRRK1 and LRRK2 in HEK293T cells and purify them 
to >90% purity. The proteins obtained show autophosphorylation activity, 
although LRRK1 appears much less active than LRRK2, as we previously 
suggested with transient transfections. We also tested whether these 
proteins are functional GTPase and preliminary data suggest that both 
LRRK1 and LRRK2 display detectable GTPase activity in vitro. Both 
LRRK2 and LRRK1 are present in the cytoplasm and in the membrane 
fraction, suggesting that activated proteins might relocalize to different 
cellular compartment(s) in order to exert their biological function. 
 
We expect that comparing the biochemical and structural properties of full-
length LRRK2 versus LRRK1 could provide both, clues on the pathogenic 
mechanism of LRRK2 and the opportunity to design and test selective 
inhibitors of LRRK2 activity.  
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Mutations in two related RNA-binding proteins, TDP-43 and FUS/TLS, 
have been linked to amyotrophic lateral sclerosis (ALS). Both proteins 
formed cytoplasmic inclusions and caused toxicity in yeast cells. Based on 
these properties, we designed a functional screen in yeast to identify new 
human genes associated with the pathogenesis of ALS. The human 
proteome contains at least 213 proteins harboring RNA recognition motifs 
(RRM proteins), including FUS/TLS and TDP-43. To find additional 
candidates with properties similar to TDP-43 and FUS/TLS, we expressed 
132 human RRM proteins in yeast and identified 35 that formed 
cytoplasmic inclusions and were toxic. Sequence analysis of two of these 
genes, EWSR1 (Ewing sarcoma breakpoint region 1) and TAF15 (RNA 
polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa), 
in sporadic ALS patients identified two variants (G511A and P552L) in 
EWSR1 and two variants in TAF15 (G391E and R408C). None of these 
variants were found in over 5,000 healthy control individuals. We also 
provide evidence that EWSR1 and TAF15 have similar in vitro and in vivo 
properties as TDP-43 and FUS, can confer neurodegeneration in 
Drosophila, and that disease-associated variants affect localization of each 
respective protein in motor neurons. Postmortem analysis of sporadic ALS 
cases revealed cytoplasmic mislocalization of EWSR1 and TAF15. Taken 
together, these data suggest that these newly identified variants are disease-
associated mutations. The identification of mutations in two additional 
RRM proteins underscores a key role for RNA metabolism defects in ALS. 
Further, the analysis of additional genes identified in the yeast functional 
screen will facilitate ALS disease gene discovery and provide new insights 
into the pathogenic mechanisms of ALS, leading to more comprehensive 
treatment approaches. 
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Alzheimer’s disease, the most prevalent form of dementia and a leading 
cause of death for elderly individuals, is marked by the accumulation of 
neuritic plaques in the brain. Amyloid fibers of Aβ42 peptide comprise 
these plaques, and prefibrillar soluble oligomeric species of Aβ42 are also 
associated with brain impairment. There is currently no treatment to directly 
eradicate these assemblies. The small molecule 4,5-dianilinophthalimide 
(DAPH-1) has been found to possess anti-amyloid properties for Aβ42, so 
we sought to investigate analogs of DAPH-1 to determine if altering the 
constituent groups could enhance these effects. During assembly, DAPH-1 
and analogs redirect Aβ42 oligomers into off-pathway aggregates. DAPHs 
also prevent amyloid fiber formation and can even remodel existing fibers. 
Certain analogs are more effective at antagonizing Aβ42 fibers, and, further, 
enhanced remodeling correlates with greater reduction of fiber toxicity. 
Further characterization of these analogs is required to determine their 
bioavailability and efficacy in vivo. 
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Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative 
disease with no effective treatments or cure. Recently TAR-DNA binding 
protein 43 (TDP-43) was identified as the major component of ALS 
inclusions. Moreover, mutations in TDP-43 have been associated with both 
sALS and fALS. To gain insight into the mechanisms by which mutations 
in TDP-43 lead to motorneuron degeneration we have generated Drosophila 
lines expressing wild type, mutant and human splice variants of TDP-43 
under the GAL4/UAS system. We have also investigated the phenotype 
associated with loss of TDP-43 function using tissue specific RNAi knock-
down of the two Drosophila homologues of TDP-43, TBPH and CG7804. 
We find clear differences in the cellular localization of the different TDP43 
splice variants. Moreover, we find that it is the lack of nuclear TDP-43 
rather than the presence of TDP-43 aggregates that is linked to lethality. 
Current studies are focused on studying the role of TDP-43 in neuronal 
development and degeneration in these Drosophila TDP-43 models of ALS 
pathogenesis. 
 
*Authors contributed equally 
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Loss of cholinergic neurons in the basal forebrain is one of the 
neuropathological hallmarks of Alzheimer’s disease and is an important 
determinant of the cognitive decline in patients. In the present studies we 
characterised the IgG129-Saporin model as an animal model for the 
cholinergic neuropathology and cognitive symptomatology in Alzheimer’s 
disease. This model is based on ablation of cholinergic neurons in the rat 
forebrain that express Nerve Growth Factor receptor (NGFr) with the 
neurotoxin IgG192-Saporin, a conjugate between IgG192, an antibody to 
the low affinity neurotrophin receptor (p75NGFr), and the ribosome 
inactivating protein saporin. Bilateral, intracerebroventricular IgG192-
Saporin injections caused a reproducible depletion of cholinergic neurons in 
the hippocampus and prefrontal cortex as measured by a 70 – 90% 
downregulation of choline acetyltransferase (ChAT) activity and a complete 
loss of NGFr expression in the basal forebrain as shown by 
immunohistochemistry. We assessed the integrity of two cognitive domains 
affected in Alzheimer’s disease, namely executive function and episodic 
memory, by the attentional set-shifting and the Morris water maze tasks, 
respectively. In the attentional set-shifting task, which is dependent on the 
prefrontal cortex, IgG192-Saporin lesioned rats showed a distinct 
impairment in the extradimensional shift. In the water maze task, reflecting 
hippocampus-dependent visuospatial memory, IgG192-Saporin lesioned 
rats displayed a deficit in the acquisition phase. Studies are ongoing to 
characterise IgG192-Saporin lesioned rats over a broader range of cognitive 
domains. The present findings indicate that the IgG192-Saporin animal 
model, characterised by early cholinergic neuropathology and concurrent 
cognitive deficits, mimics some of the key hallmarks of Alzheimer’s 
disease. 
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Mutations in two DNA/RNA binding proteins, TAR DNA-binding protein 
(TDP-43) and Fused in Sarcoma (FUS) have been identified as primary 
causes of inherited Amyotrophic Lateral Sclerosis (ALS) and have led to 
what is likely to be a paradigm shift in efforts to understand the 
pathogenesis of ALS. The current evidence worldwide has produced the 
leading hypothesis that mutations in TDP-43 or FUS/TLS contribute to 
disease by causing aberrations in RNA processing. One key unanswered 
question underlying ALS pathogenesis is why motor neurons are exquisitely 
sensitive to mutation in either protein: how is motor neuron biology altered 
by either the loss of or mutation in either of these genes? The weight of 
current evidence strongly supports the view that there must be a component 
of motor neuron biology that selectively renders them sensitive to 
alterations in TDP-43 or FUS/TLS-dependent RNA processing. To 
determine the role(s) of these proteins in motor neurons, mutant expressing 
motor neurons have been obtained by differentiation of blastocyst-derived 
embryonic stem cell lines carrying transgenes encoding wild-type or mutant 
human TDP-43 (familial mutant M337V or sporadic mutant Q331K, each 
driven by the prion promoter) and GFP expressed under the control of the 
motor neuron specific Hb9 promoter. The resulting stem cells were then 
induced to differentiate into motor neurons (by exposure to retinoic acid and 
sonic hedgehog) and enriched populations of TDP-43-expressing motor 
neurons obtained by sorting of GFP-positive cells with flow cytometry. 
Alterations in RNA expression and splicing patterns have been analyzed. 
Furthermore, immunoprecipitation of myc-tagged TDP-43 from motor 
neurons has identified RNA targets that are differentially bound by wild-
type or mutant TDP-43. Together, this study presents a novel approach for 
identifying cell-intrinsic properties of TDP-43 in motor neurons, one of the 
most relevant cell types for understanding ALS pathogenesis. 
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Nerve growth factor (NGF) signalling is known to be important to ensure 
normal development of the retina. Additionally, NGF signalling is involved 
in supporting survival of injured retinal ganglion cells (RGCs) in the adult 
eye following glaucoma. NGF is thought to exert its pro-survival effect by 
binding to a receptor complex consisting of specific tyrosine kinase A 
(TrkA) receptor and the p75NT receptor (p75NTR). However, NGF may 
also be released in a precursor form denoted proNGF. As opposed to its 
mature form, unprocessed proNGF acts as a death-inducing ligand when 
bound to a receptor complex comprising sortilin and the p75NTR. Elevated 
intraocular pressure (IOP)-induced retinal ganglion cell death is associated 
with an acute phase of necrosis and a delayed phase of apoptosis. It has 
previously been shown that expression of both sortilin and p75NTR is 
increased after IOP-induced ischemia, suggestive of active cell death 
signalling through this receptor complex.  
We utilized sortilin knock-out (KO) mice to investigate whether loss of 
sortilin signalling would be neuroprotective in the IOP-model. We showed 
that, compared to wildtype controls, sortilin KO mice displayed 
significantly increased RGC survival two weeks following transient 
ischemia. Furthermore, in retinas isolated from injured eyes, expression of 
p75NTR and TrkA were increased and decreased, respectively, compared to 
uninjured control retinas, suggesting that pro-survival signalling through 
TrkA was reduced whereas death-signalling through p75NTR and sortilin 
was increased. These data indicate that sortilin signalling is involved in 
induction of RGC cell death following retinal ischemic injury.  
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Parkinson’s disease (PD) is one of the most common progressive 
neurodegenerative movement disorders, yet the pathogenesis of disease 
remains unclear. Several genes have been linked to hereditary forms of PD 
among which pink1. pink1 encodes for a mitochondrial localized 
serine/threonine kinase. Recent data indicate that Drosophila loss of 
function mutations of pink1 are viable, male sterile and show mitochondrial 
defects. These mitochondrial defects lead to muscle degeneration and 
reduced synaptic vesicle cycling in neurons. To further understand the 
relation between PINK1 and the mitochondria physiology we are isolating 
dominant suppressors and enhancers of pink1.  
As pink1 affects mitochondrial function and synaptic transmission, we are 
screening a collection of 500 mutants that affect neuronal communication, 
isolated in a forward EMS screen, for modifiers of pink1. We already 
identified one suppressor and one enhancer and we tested them for 
alleviation of or enhancement of the specific mitochondrial defects we 
observed in pink1 mutants. We found that both these modifier genes impact 
ATP level and mitochondrial membrane potential defects of pink1 mutant. 
These genetic modifiers will help us to elucidate the molecular pathways 
and interactions that control mitochondrial function especially as it impacts 
on the function and survival of neurons. 
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Although oxidative stress is a general characteristic of many 
neurodegenerative diseases including Alzheimer’s disease (AD), the 
repertoire of disease-specific redox perturbations is poorly understood. 
Astrocytes play a critical role in redox homeostasis in brain and provide 
neurons with cysteine needed for glutathione (GSH) synthesis. In this study, 
we demonstrate that the signature of astrocytic redox responses provoked 
by amyloid β (Aβ) is distinct from that of a general oxidative insult (by the 
organic peroxide, tertiary-butylhydroperoxide (t-BuOOH)). Acute Aβ 
treatment increased levels of cystathionine β-synthase (CBS) and enhanced 
transsulfuration flux in contrast to repeated Aβ exposure, which decreased 
CBS and catalase protein expression level. Although t-BuOOH also 
increased transsulfuration flux, CBS levels were unaffected. The net effect 
of Aβ treatment was an oxidative shift in the intracellular GSH:glutathione 
disulfide redox potential in contrast to a reductive shift in response to 
peroxide treatment. In the extracellular compartment, Aβ treatment 
enhanced cystine uptake and cysteine accumulation, which was not 
observed with t-BuOOH and resulted in remodeling of the extracellular 
cysteine/cystine redox potential in the reductive direction. The redox 
changes elicited by Aβ but not peroxide were associated with enhanced 
DNA synthesis albeit without cell division, suggesting an S to G2/M phase 
block in the cell cycle. Our study suggests that the alterations in astrocytic 
redox status could compromise the neuroprotective potential of astrocytes 
and may be a potential new target for therapeutic intervention in AD. 
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Loss of function mutations in the ALS2 gene accounts for a number of 
juvenile motor neuron diseases, such as a juvenile recessive form of ALS 
(ALS2), a rare juvenile recessive form of primary lateral sclerosis (PLSJ), 
and an infantile-onset ascending hereditary spastic paralysis (IAHSP). Thus, 
its gene product ALS2/alsin may play an important role in maintenance 
and/or survival of motor neurons. ALS2 is a guanine nucleotide exchange 
factor for the small GTPase Rab5 and involves in macropinocytosis-
associated endosome fusion and trafficking, anti-cytotoxicity, and neurite 
outgrowth. However, the physiological role of ALS2 and molecular 
mechanisms underlying motor dysfunction remain unclear. We here 
identified ALS2 as a novel regulator for endolysosomal protein degradation. 
Genetic ablation of Als2 in SOD1H46R transgenic mice aggravated the 
mutant SOD1-associated disease symptoms such as body weight loss and 
motor dysfunction, leading to the earlier death. Light and electron 
microscopic examinations revealed the presence of degenerating and/or 
swollen spinal axons accumulating granular aggregates and 
autophagosome-like vesicles in early- and even pre-symptomatic SOD1H46R 
mice. Further, enhanced accumulation of insoluble high molecular weight 
SOD1, poly-ubiquitinated proteins, and macroautophagy-associated 
proteins such as polyubiquitin-binding protein p62/SQSTM1 and a lipidated 
form of light chain 3 (LC3-II), emerged in ALS2-deficient SOD1H46R mice. 
Intriguingly, ALS2 was colocalized with LC3 and p62, and partly with 
SOD1 on autophagosome/endosome hybrid compartments called 
amphisomes, and loss of ALS2 significantly lowered the lysosome-
dependent clearance of LC3 and p62 in cultured cells. Based on these 
observations, disturbance of the endolysosomal system by ALS2 loss may 
exacerbate the SOD1H46R-mediated neurotoxicity by accelerating the 
accumulation of immature vesicles and misfolded proteins in the spinal 
cord. We propose that ALS2 is implicated in endolysosomal trafficking 
through the fusion between endosomes and autophagosomes, thereby 
regulating endolysosomal protein degradation in vivo. 
 
This work was supported by the Tokai University General Research Organization, 
JSPS, and MHLW (Japan). 
 34 
INSIGHTS INTO TDP-43 PROTEINOPATHY USING DROSOPHILA 
MELANOGASTER AS A MODEL SYSTEM. 
 
Keith A Hanson, Sang Hwa Kim, David A Wassarman, Randal S Tibbetts  
 
University of Wisconsin, Madison, Department of Pharmacology, Madison, 
WI, 53706 
 
TDP-43 (43 kDa TAR DNA-binding protein) is a major constituent of 
ubiquitin-positive cytosolic aggregates present in neurons of patients with 
amyotrophic lateral sclerosis (ALS) and ubiquitin-positive fronto-temporal 
lobar degeneration (FTLD-U). Inherited mutations in TDP-43 have been 
linked to familial forms of ALS, indicating a key role for TDP-43 in disease 
pathogenesis. We have utilized Drosophila melanogaster to develop an in 
vivo model of TDP-43 proteinopathy. Expression of wild-type human TDP-
43 protein in Drosophila motor neurons led to motor dysfunction and 
dramatic reduction of lifespan; these phenotypes were enhanced by 
coexpression of Ubiquilin 1, a previously identified TDP-43-interacting 
protein. Interestingly, ectopically expressed TDP-43 was exclusively 
localized to motor neuron nuclei, suggesting that expression of wild-type 
TDP-43 alone is detrimental even in the absence of cytosolic aggregation. 
We are currently exploring the role that gene expression changes may play 
in TDP-43 toxicity. Using both constituitive and inducible systems, we have 
identified genes that are changed in vivo upon TDP-43 expression, with the 
goal of identifying genes or pathways whose modification can alleviate 
TDP-43-dependent phenotypes. Our findings demonstrate that TDP-43 
exerts cell autonomous neurotoxicity in Drosophila and suggest that dose-
dependent alterations of TDP-43 nuclear function underlie motor neuron 
death in ALS. 
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DEVELOPING APPLICATIONS FOR PRIMARY ASTROCYTES TO 
ENABLE DRUG DISCOVERY 
 
Spencer Hermanson, Lucas Chase, Kun Bi  
 
Life Technologies Corporation, Primary and Stem Cell Systems, Cell 
Systems Division, Madison, WI, 53719 
 
Astrocytes are a type of glial cell that play important roles in brain function. 
They regulate the extracellular ionic and chemical environment, respond to 
CNS injury, and are a major factor in the pathogenesis of ischemic neuronal 
death. Astrocytes remain as one of the most active research areas in 
neuroscience. Human astrocytes provide an excellent source of primary 
human cells and are the beginnings of a physiologically relevant system to 
use for a wide range of studies. However, the use of primary astrocytes has 
not been reported in high-throughput drug discovery settings. Life 
Technologies has developed human brain progenitor-derived astrocytes. To 
better enable our customers, we hypothesized that human astrocytes could 
be combined with BacMam-mediated gene expression and/or LanthaScreen 
cellular technology for high-throughput assays. To test susceptibility of 
human astrocytes to BacMam mediated gene expression, a series of 
transduction conditions were performed using BacMam virus for GFP-
tagged p53. Cells were monitored for GFP expression using fluorescence 
microscopy for a period of 72 hours. To perform high-throughput assay 
feasibility, human astrocytes were seeded in a 384-well microplate and the 
astrocytes were transduced with BacMam virus expressing p53 under 
optimized conditions. Cells were treated with DNA damaging reagent to 
induce post-translational modifications of p53. Levels of post-translational 
modifications were quantitated using LanthaScreen cellular assay 
technology. To investigate potential for disease modeling, human astrocytes 
were transduced with BacMam viruses of Parkinsons-related disease target 
LRRK2 and it’s putative substrates including alpha-synuclein. Over 
expression was confirmed by western blot and fluorescence microscopy. 
These studies have shown that human brain progenitor-derived astrocytes 
are amenable to BacMam delivery system and can be applied to high-
throughput assays such as cellular LanthaScreen assays. This data shows 
that combining human astrocytes, BacMam technology and LanthaScreen 
cellular assays offers a physiologically relevant high-throughput compatible 
workflow for customers interested in neuroscience related disease modeling 
and drug screening.  
 
“FOR RESEARCH USE ONLY. NOT INTENDED FOR ANY ANIMAL 
OR HUMAN THERAPEUTIC OR DIAGNOSTIC USE.”  
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β-secretase inhibition is a potential disease-modifying therapy for Alzheimer’s 
disease (AD). The cysteine protease, cathepsin B, is hypothesized to be a β-
secretase, which cleaves the normal (wild-type) β-secretase site sequence in 
amyloid precursor protein (APP) to produce beta-amyloid peptides (Aβ). 
Evidence for cathepsin B being a β-secretase includes the fact that deleting the 
gene or chemically inhibiting the activity decreases brain Aβ and the 
carboxyterminal β-secretase fragment (CTFβ) in animal models. Moreover, 
inhibiting cathepsin B activity improves the memory deficit and reduces brain 
plaque in transgenic mice expressing APP containing the normal β-secretase 
site sequence. However, it is not clear if those effects are directly due to 
cathepsin B inhibition or an off-target inhibition of the aspartyl β-secretase, 
BACE1. To evaluate that issue, we studied the effect of oral administration of 
the potent cysteine protease inhibitor, E64d, to either guinea pigs, which are a 
model of normal human Aβ production, or to transgenic mice expressing human 
APP containing the normal β-secretase site and the London mutant γ-secretase 
site sequences, which overproduce Aβ and mimic AD behavior and pathology. 
Guinea pigs gavaged once–a-day for a week with E64d had a dose response 
reduction in brain, CSF and plasma Aβ(40) and Aβ(42), brain CTFβ and brain 
cathepsin B activity but increased brain BACE1 activity. Paired analysis from 
individual guinea pigs showed a strong positive correlation between brain 
Aβ(40) or Aβ(42) and brain cathepsin B activity but a weak negative correlation 
with brain BACE1 activity. Feeding young (6 month old) or old (12 month old) 
transgenic mice chow doped with E64d (10 mg/kg/day) for either 1 or 3 months 
also reduced brain, CSF and plasma Aβ(40) and Aβ(42), brain CTFβ and brain 
cathepsin B activity but increased brain BACE1 activity in both age groups. 
Paired analysis of individual mice showed a strong positive correlation between 
brain Aβ(40) or Aβ(42) and brain cathepsin B activity but only a weak negative 
correlation with brain BACE1 activity. Importantly, those feedings also 
improved the memory deficit and brain plaque in both young and old transgenic 
mice. These data show that the effects of inhibiting cathepsin B are not due to 
an off-target inhibition of BACE1. More importantly, these data support the 
potential of cathepsin B inhibitors generally and E64d specifically for treating 
AD since most AD patients express APP containing the normal β-secretase site 
sequence. 
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Beta-amyloid (Abeta) in brain is a major factor involved in Alzheimer’s 
disease (AD) that results in severe memory deficit. Our recent studies 
demonstrate pharmacogenetic differences in the effects of inhibitors of 
cathepsin B to improve memory and reduce Abeta in different mouse 
models of AD. The inhibitors improve memory and reduce brain Abeta in 
mice expressing the wild-type (WT) beta-secretase site of human APP, 
expressed in most AD patients. However, these inhibitors have no effect in 
mice expressing the rare Swedish (Swe) mutant APP. Knockout of the 
cathepsin B decreased brain Abeta in mice expressing WT APP, validating 
cathepsin B as the target. The specificity of cathepsin B to cleave the WT 
beta-secretase site, but not the Swe mutant site, of APP for Abeta 
production explains the distinct inhibitor responses in the different AD 
mouse models. In contrast to cathepsin B, the BACE1 beta-secretase prefers 
to cleave the Swe mutant site. Discussion of BACE1 data in the field 
indicate that they do not preclude cathepsin B as also being a beta-secretase. 
Cathepsin B and BACE1 may participate jointly as beta-secretases for 
production of Abeta that is secreted from neurons and accumulates in AD 
brains. Significantly, the majority of AD patients express normal WT APP 
and, therefore, inhibitors of cathepsin B represent candidate drugs for AD. 
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Background: Traumatic brain injury (TBI) causes acute inflammatory 
responses that result in an enduring cascade of secondary neuronal loss and 
behavioral impairments. It has been reported that progesterone (PROG) can 
inhibit the increase of some inflammatory cytokines and inflammation-
related factors induced by TBI. Toll-like receptors (TLRs) play a critical 
role in the induction and regulation of immune/inflammatory responses. 
Therefore, in the present study, we examined the genomic profiles of TLR-
mediated pathways in traumatically injured brain and PROG’s effects on 
these genes. Methods: Bilateral cortical impact injury to the medial frontal 
cortex was induced in C56BL/6J mice. PROG was injected (i.p., 16mg/kg 
body weight) at 1 and 6 h after surgery. Twenty-four hours post-surgery, 
mice were killed and peri-contusional brain tissue was harvested for 
genomic detection. RT-PCR arrays were used to measure the mRNA of 84 
genes in TLR-mediated pathways. Results: We found that 2 TLRs (TLR1 
and 2), 5 adaptor/interacting proteins (CD14, MD-1, HSPA1a, PGRP and 
Ticam2) and 13 target genes (Ccl2, Csf3, IL1a, IL1b, IL1r1, IL6, IL-10, 
TNFa, Tnfrsf1a, Cebpb, Clec4e, Ptgs2 and Cxcl10) were significantly up-
regulated after injury. Administration of PROG significantly down-
regulated 3 of the 13 target genes after TBI (Ccl-2, IL-1b and Cxcl-10), but 
did not affect the expression of any of the detected TLRs or 
adaptor/interacting proteins. Rather, PROG up-regulated the expression of 
one TLR (TLR9), 5 adaptor/interacting proteins, 5 effectors and 10 
downstream target genes. Conclusion: The results demonstrate that TBI 
can increase gene expression in TLR-mediated pathways. Moreover, PROG 
does not down-regulate the increased TLRs and their adaptor proteins in 
traumatically injured brain. The reduction of the observed inflammatory 
cytokines by PROG does not appear to be the result of inhibiting TLRs and 
their adaptors in the acute stage of TBI.  
 
Key words: Toll-like receptors, Progesterone, traumatic brain injury, inflammation, 
neuroprotection, mouse  
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supported by a gift from BHR Pharma. 
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Tat activating regulatory DNA-binding protein (Tardbp or TDP-43), an 
essential RNA binding protein, has been associated with the 
pathophysiology of neurodegenerative diseases, including amyotrophic 
lateral sclerosis (ALS) and frontotemporal lobar degeneration with 
ubiquitin-positive inclusions (FTLD-U). Understanding the biology of 
TDP-43 in the nervous system will be critical for clarifying the 
pathophysiology of this RNA binding protein in neurodegenerative 
diseases. Toward this end, we have begun to address the physiological role 
of TDP-43 and its downstream targets. Although our previous efforts 
revealed important roles of TDP-43 in regulation of body fat metabolism 
and formation of SMN-associated Gemini of coiled bodies, the 
physiological role of TDP-43 in the brain remains unknown. To examine 
the function of TDP-43 in forebrains of mice, we crossbred our conditional 
TDP-43 knockout mice with CamKIIa-iCre transgenic mice and we are 
currently analyzing the consequence of the lack of TDP-43 in this brain 
region and outcomes of these findings will be presented. 
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Majority of fast excitatory synaptic transmission in the mammalian brain is 
mediated by a class of molecules called ionotropic glutamate receptors, 
which include N-methyl-D-aspartate (NMDA) receptors. NMDA receptors 
are hetero-tetrameric ion channels that are composed of two GluN1 subunits 
and two GluN2 (A-D) subunits or GluN3 subunits. NMDA receptors play 
key roles in numbers of important processes including synaptic plasticity 
and development in normal state, whereas excessive activity of NMDA 
receptors is associated with ischemic brain injury and neurodegenerative 
diseases including Parkinson’s disease, Alzheimer’s disease and 
Huntington’s disease. Activity of NMDA receptor is tightly controlled 
through multiple pathways. One such mechanism is allosteric modulation 
through binding of small molecules to the extracellular amino terminal 
domain (ATD) in a subtype specific manner, i.e. polyamines and protons 
bind GluN1, Zn2+ binds both GluN2A and GluN2B, and 
phenylethanolamine compounds bind GluN2B. To understand the 
molecular mechanism of the ATD-dependent allosteric modulation of 
NMDA receptors, we have solved the structures of GluN2B ATD in the 
zinc-bound and -free forms. The structures reveal an overall clamshell 
architecture with a unique domain orientation distinct from the non-NMDA 
receptor ATDs and molecular determinants for the zinc binding site, ion 
binding sites, and the architecture of the putative phenylethanolamine 
binding site. 
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A well organized nervous system is critical for accurate brain function as 
numerous psychiatric and neurological diseases are thought to arise from 
morphological defects in synaptic architecture and connectivity. We are 
therefore indentifying molecules and their effectors involved in regulating 
synaptic morphology. Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) is a 
membrane lipid is involved in several important signaling pathways; and its 
metabolism is associated with neurological diseases including Alzheimer’s 
Disease and Lowe Syndrome. However, the role of this lipid in the 
regulation of synapse morphology is ill-defined. Here we identify PI(4,5)P2 
as a gatekeeper of neuromuscular junction (NMJ) size and potentially also 
other synaptic types. We show that PI(4,5)P2 levels in neurons are critical in 
restricting synaptic growth by localizing and activating presynaptic 
Wiscott-Aldrich Syndrome Protein (WSP). This function of WSP is 
independent of Bone Morphogenetic Protein (BMP) signaling but is 
dependent on Tweek, a novel neuronally expressed protein. Loss of 
PI(4,5)P2-mediated WSP-activation results in increased formation of 
moesin-GFP patches that concentrate at sites of bouton growth. Based on 
pharmacological and genetic studies, moesin patches mark polymerized 
actin accumulations and correlate well with NMJ size. Taken together, we 
propose a model where PI(4,5)P2 and WSP-mediated signaling at 
presynaptic termini controls actin-dependent synapse growth in a pathway 
at least in part in parallel to synaptic BMP signaling.  
 
*T.M.K and R.L.H. contributed equally to this work. 
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Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative 
disease that preferentially targets motor neurons. Dominant mutations in 
two related RNA-binding proteins, TDP-43 (43 kDa TAR DNA-binding 
domain protein) and FUS/TLS (fused in sarcoma/translated in liposarcoma) 
cause a subset of ALS. The convergent ALS phenotypes associated with 
TDP-43 and FUS/TLS mutations are suggestive of a functional relationship. 
Consistent with this idea, recently published studies from several 
laboratories, including ours, have demonstrated physical interaction 
between TDP-43 and FUS/TLS in mammalian cells. Our work 
demonstrated that TDP-43 and FUS/TLS selectively interact within the 
context of a 300 kDa TDP-43 complex in a manner that requires the TDP-
43 Gly-rich domain, which is the target of most ALS-associated mutations 
in the protein. Cleavage products of TDP-43, which have received interest 
as disease determinants in ALS, cofractionated with the 300 kDa TDP-43 
complex and retained interaction with FUS/TLS, but were excluded from a 
large (2 MDa) TDP-43 ribonucleoprotein complex. Finally, both TDP-43 
and FUS/TLS were required for maximal expression of HDAC6, a 
previously identified substrate of TDP-43, and both factors associated with 
HDAC6 mRNA in vitro and in cellulo. These findings support a model in 
which TDP-43 and FUS/TLS collaborate, potentially within the context of a 
core biochemical complex, to regulate a subset of RNA substrates. An 
implication of these findings is that participation of TDP-43 and FUS/TLS 
within common biochemical pathways may contribute to convergent ALS 
phenotypes associated with their respective gene mutations. Current studies 
are focused on establishing the impact of ALS-associated mutations on 
TDP-43 complex forming potential, including interaction with FUS/TLS, as 
well as further elucidation of TDP-43 core complexes. 
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Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that 
results in progressive loss of memory and accumulation of neurotoxic β-
amyloid (Aβ) peptides in brain. The abnormal accumulation of Aβ peptides 
has been demonstrated as a major factor in the disease, based largely on 
studies of transgenic mouse models which overproduce Aβ, resulting in 
memory deficit and amyloid plaque brain pathology similar to that observed 
in AD patients. Aβ peptides are generated from the amyloid precursor 
protein (APP) by proteases known as β- and γ-secretases, which release the 
N- and C-termini of Aβ, respectively. The aspartyl protease BACE 1 is a β-
secretase, but it is relatively inefficient at cleaving the wt β-secretase site. 
The cysteine protease cathepsin B (CatB) has been proposed as an 
alternative candidate β-secretase, which resides in the regulated secretory 
pathway of neurons, where it produces Aβ by efficient cleavage of the wt β-
secretase site of APP. Inhibitors of cathepsin B significantly reduce brain 
levels of Aβ40 and Aβ42, and also reduce brain levels of C-terminal β-
secretase fragment (CTFβ) derived from APP; notably, these inhibitors 
improve memory deficit in a AD mouse model expression human APP with 
wt β-secretase site. In this study, we have generated transgenic mice 
expressing either the wildtype (APPwtln) or mutant (APPmtswe/ln) β-secretase 
site form of APP and sufficient or deficient in either cathepsin B or BACE-
1 to understand the mechanisms of Aβ generation. APPwt/CatB-/- mice and 
APPmt/BACE-/- mice showed decreases in Aβ peptide levels (both 1-40 and 
1-42), decreases in CTFβ, increases in sAPPα, reduced levels of amyloid 
plaques and improved cognitive behavior compared to the sufficient 
animals. Other combinations of the mice (APPmt/CatB+/+, APPmt/CatB-/- or 
APPwt/BACE+/+, APPwt/BACE-/-) did not have altered levels. These data 
suggest that both cathepsin B and BACE-1 are true β-secretases but that 
they function at different levels in the generation of Aβ peptides. These data 
strongly suggest that a therapeutically acceptable method of inhibiting Cat 
B can be developed to reduce brain Aβ in AD patients. 
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The combinatory apposition of neuromodulatory, inhibitory and excitatory 
neurons within the same micro circuit greatly expands the repertoire of 
strategies available to the CNS for the homeostatic regulation of circuit 
performance. It also raises questions about how the circuit type specific relative 
proportion of the constituent neuronal subtypes, which display very different 
survival risks, is maintained throughout life. We tested the hypothesis that target 
derived survival factor signaling within microcircuits of the adult striatum plays 
a role in the homeostatic maintenance of circuit architecture.  
In the striatum, the concerted action of the neuromodulators dopamine (DA), 
supplied by the ascending, mesencephalic dopamine system and acetylcholine 
(ACh), supplied by locally projecting, tonically active interneurons (TANS), 
together with gabaergic input from a set of local interneurons provides the 
means by which experience shapes the strength of the glutamatergic drive of 
medium spiny projection neurons (MSNs).  
Using genetic gene expression - tracer and conditional ablation strategies 
together with acute pharmacological and neurotoxicological perturbations we 
found that the mature mesencephalic - striatal microcircuit embodies a 
reciprocal, trophic factor support loop with homeostatic properties that is 
absolutely required for the interdependent maintenance of TANS and fast 
spiking gabaergic interneurons (FS) in the striatum on one side and DA- 
neurons of the ventral midbrain on the other. One arm of this loop is provided 
by expression of the axonaly transported cell signaling factor sonic hedgehog 
(Shh) by all mesencephalic DA neurons, which signals to TANS and FS 
neurons throughout life and whose expression is repressed by signals emanating 
from TANS. The other arm is provided by the glia derived, dopaminotrophic 
factor (GDNF), which is expressed by all TANS throughout life and whose 
expression is repressed by DA – neuron produced Shh. The chronic, genetic 
interruption of trophic factor signaling causes late life onset, progressive loss of 
TANS, FS and DA neurons. Despite a correlated degeneration of TANS and 
DA neurons we find highly dynamic alterations in ACh and DA dependent 
neuronal signaling whose functional consequences on locomotion activity and 
gait dynamics can be ameliorated by DA substitution and anti cholinergic 
pharmacology of proven efficacy in the management of Parkinson’s Disease.  
Our work provides in vivo evidence for the maintenance of the relative 
proportions of the constituent members of neuronal assemblies through 
homeostatic trophic strategies and suggests that the maintenance of circuit 
specific, relative neuronal proportions trumps the importance of absolute 
neuronal survival.  
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Neurodegenerative disorders characterized by neuronal and glial lesions 
containing aggregated pathological TDP-43 protein in the cytoplasm, 
nucleus, or neurites are collectively referred to as TDP-43 proteinopathies. 
Lesions containing aggregated TDP-43 protein are a hallmark of 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration 
with TDP-43 inclusions (FTLD-TDP). In addition, mutations in human 
TDP-43 cause ALS. We have developed a C. elegans model of TDP-43 
proteinopathies to study the cellular, molecular, and genetic underpinnings 
of TDP-43 mediated neurotoxicity. Expression of normal human TDP-43 in 
all C. elegans neurons causes moderate motor defects, while ALS-mutant 
G290A, A315T, or M337V TDP-43 transgenes cause severe motor 
dysfunction. The model recapitulates some characteristic features of ALS 
and FTLD-TDP including age-induced decline in motor function, decreased 
lifespan, and degeneration of motor neurons accompanied by 
hyperphosphorylation, truncation, and ubiquitination of TDP-43 protein that 
accumulates in detergent insoluble protein deposits. In C. elegans, TDP-43 
neurotoxicity is independent of activity of the cell death caspase CED-3. 
Furthermore, phosphorylation of TDP-43 at serine residues 409/410 drives 
mutant TDP-43 toxicity. This model provides a tractable system for further 
dissection of the cellular and molecular mechanisms underlying TDP-43 
neuropathology. 
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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease 
affecting motor neurons. The G93A mutation in the Cu/Zn superoxide 
dismutase (SOD1) gene causes a version of familial ALS. The SOD1 G93A 
transgenic mouse harboring this human mutation is a well-characterized 
mouse model of ALS. Previous reports have shown that inhibition of 
epidermal growth factor receptor (EGFR) leads to neuroprotection of retinal 
ganglion cells in a model of glaucomatous optic neuropathy (Liu et al., 
2006), and to improved recovery in a spinal cord injury model (Erschbamer 
et al., 2007). Furthermore, we found that EGFR inhibitors such as erlotinib 
(Tarceva) protect neurons from axon loss in an NGF-dependent culture 
model of dorsal root ganglion (DRG) neurons. Thus, we assessed the 
therapeutic potential of this compound in the SOD1 mouse model in its 
ability to (1) slow motor neuron denervation at the neuromuscular junction, 
(2) delay motor neuron cell death, (3) delay disease onset, (4) improve 
motor behavior during disease progression, and (5) extend survival. 
Phospho-EGFR staining was reduced in the spinal cords of erlotinib-treated 
mice. Critically, erlotinib treatment slowed neuromuscular denervation and 
delayed disease onset in SOD1 mice. We are currently assessing whether 
erlotinib also extends lifespan and improves motor function in symptomatic 
SOD1 transgenic mice.  
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Amyotrophic lateral sclerosis (ALS) is a crippling neurodegenerative 
disease that attacks motor neurons. While mostly a sporadic disorder, 
mutations in several genes, such as RNA binding protein encoding gene 
TDP-43, have been identified in some ALS case. Aggregated TDP-43 is 
found in degenerating neurons of most ALS patients, and mutations in the 
TDP-43 gene have been linked to some rare familial and sporadic forms of 
ALS. Recently, we have found that ataxin 2, a polyglutamine (polyQ) 
protein, whose polyQ repeat expansions cause spinocerebellar ataxia type 2 
(SCA2), is a potent modifier of TDP-43 toxicity in yeast and fly; 
expansions of 27-33Qs in the ataxin 2 gene (ATXN2) are significantly 
associated with increased risk for ALS. These data argue that ATXN2 is a 
new and relatively common ALS genetic risk factor. In addition to ataxin 2 
and SCA2, there are other polyQ diseases caused by the CAG repeat within 
the coding region of the respective genes. Is the effect of polyQ expansions 
in ALS specific to ataxin 2 or do polyQ expansions in other genes also 
increase risk for ALS? If it is specific to ataxin 2 this suggests that the 
protein’s normal function (i.e., regulation of RNA metabolism) is key. On 
the other hand, if polyQ expansions in other genes also occur, then it 
suggests that the expansion is key, perhaps by perturbing proteostasis 
networks in a general way. To test this, we choose four genes with polyQ 
expansions: ataxin 1, ataxin 3, ataxin 6, and Huntington. In addition, we 
analyzed two other genes, PABPC1 and PABPC3, which encode 
cytoplasmic polyA binding proteins. These proteins have been found to 
physically interact with ataxin 2 and also harbor trinucleotide repeats 
encoding alanine (polyA) instead of polyQ. We assessed the polyQ or 
polyA repeat lengths in these proteins by PCR and Genescan analysis of 
several hundred ALS and healthy controls. Other than ataxin 2, we did not 
identify a significant correlation between the incidence of ALS and 
trinucleotide repeat expansions in these other genes. Taken together, these 
data suggest that the effects of ataxin 2 polyQ expansions on ALS risk are 
likely to be rooted in the biology of ataxin 2 and/or ataxin 2-specific 
interactions rather than the presence of a polyQ repeat per se. These 
findings have important consequences for understanding of the role of 
ataxin 2 in ALS pathogenesis and provide a new framework for future 
mechanistic studies. 
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Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) 
are neurodegenerative diseases sharing overlapping clinical and 
pathological characteristics. Mutations in two wildly expressed nucleic-acid 
binding proteins, TDP-43 and FUS/TLS, cause an inherited form of ALS, 
and abnormal aggregations of these two proteins are present in both ALS 
and FTD independent of the mutations. To determine FUS/TLS pathogenic 
mechanisms, expression of wild type and two ALS-linked mutations 
(R514G and R521C) in FUS/TLS was achieved in the nervous system of 
mice (using a murine prion gene promoter). Lines of comparable wild type 
or mutant human FUS/TLS accumulation were established. Mutant 
FUS/TLS causes abnormal posture, clasping and hindlimb spread 
phenotypes. Aged wild type and mutant FUS/TLS expressing animals 
develop abnormal gait, accompanied by glia activation along with reduced 
numbers of motor and sensory axons. Both wild type and ALS-linked 
FUS/TLS accumulated in urea insoluble fractions and showed altered 
distribution, but do in different ways. Taken together, our results 
demonstrate that human wild type or ALS-linked mutations in FUS/TLS 
trigger neurodegeneration in mice and suggest that the underlying 
mechanisms for which wild type and ALS-linked mutants cause 
neurodgeneration are distinct, providing a molecular basis for FUS 
involvement in pathogenesis in the absence of mutation. 
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The human FMR1 gene contains a (CGG)n trinucleotide repeat in the 5’ 
untranslated region (5’UTR) that is responsible for a number of heritable 
disorders affecting both early neurodevelopment (FXS, OMIM #300624) 
and late-onset neurodegeneration (FXTAS, OMIM #300623). Research to 
date has revealed a basic understanding of the underlying cellular 
mechanisms of the FMR1 repeat-expansion disorders, but many knowledge 
gaps remain in these mechanisms. Bioinformatic analysis of the sequence 
composition in and around the FMR1 5’UTR suggests that an RNA/DNA 
hybrid structure (R-Loop) forms following active transcription through the 
region. Non-denaturing bisulfite sequencing reveals the presence of 
extensive, continuous single-stranded DNA spanning the 5'UTR and the 
CGG repeats in genomic DNA harvested from cultured human skin 
fibroblasts from both "normal" (CGG<55) and "premutation" (55<200) 
repeat alleles. Elimination of this single-strandedness following RNase H 
digestion demonstrates that this feature is the result of an RNA/DNA hybrid 
forming and displacing the non-template strand of DNA. This data 
introduces a previously unknown molecular feature of this locus, with 
potential implications for the associated molecular pathologies. 
 50 
GENETIC AND PHARMACOLOGIC MODULATION OF THE IIS AND 
HSF-1 PATHWAYS RESCUES MUTANT ATAXIN-3-MEDIATED 
PROTEOTOXICITY IN C. ELEGANS NEURONS 
 
Andreia Teixeira-Castro1,2, Michael Ailion2, Ana Jalles1, Andreia Neves-
Carvalho1, Richard I Morimoto3, Patricia Maciel1  
 
1University of Minho, Life and Health Sciences Research Institute (ICVS), 
School of Health Sciences, Braga, 4710-057, Portugal, 2Howard Hughes 
Medical Institute, University of Utah, Department of Biology, Salt Lake 
City, UT, 84112, 3Northwestern University Evanston, Northwestern 
University Institute for Neuroscience, Rice Institute for Biomedical 
Research, Evanston, IL, 60208 
 
The risk of developing neurodegenerative diseases increases with age. 
Although many of the molecular pathways regulating proteotoxic stress and 
longevity are well characterized, their contribution to disease susceptibility 
remains unclear. In this study, we developed a new Caenorhabditis elegans 
model of Machado-Joseph disease (MJD) pathogenesis. Pan-neuronal 
expression of mutant ATXN3 leads to neuron subtype-specific aggregation 
and neurological dysfunction. Analysis of specific neurons reveals that 
there is a very consistent pattern of neuronal susceptibility to the expression 
of both full-length and truncated forms of mutant ataxin-3. Importantly, 
when compared with the expression of polyQ-alone proteins, we have found 
a distinct vulnerability to pathogenic ATXN3 with dorsal nerve cord and 
certain sensory processes being highly affected, suggesting that ATXN3 
protein flanking sequences and neuronal cell-intrinsic factors modulate 
polyQ-mediated pathogenesis.  
Age strongly modifies disease manifestation and protein aggregation in our 
model. We have found that reduction of Insulin/Insulin Growth Factor 
(IGF)-1-like signaling and activation of the Heat Shock Factor-1 pathways, 
genetically or pharmacologically, protect against developing the disease, 
and this constitutes key information for the design of potential new 
therapies in MJD.  
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Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia type 
3 (SCA3), is an autosomal dominant neurodegenerative disorder caused by 
the expansion of a polyglutamine tract (polyQ) in the C-terminus of the 
ATXN3 gene product, ataxin-3. Although ataxin-3 is ubiquitously 
expressed, only restricted neuronal populations of the central nervous 
system are affected in the disease. We have generated three lineages of 
transgenic mice expressing human ataxin-3 with an expanded CAG tract 
under the control of the CMV promoter: CMVMJD83, CMVMJD94 and 
CMVMJD135, carrying Q83, Q94 and Q135 polyQ stretches, respectively.  
Behavioral analysis revealed that transgenic CMVMJD83 mice did not 
manifest motor deficits during their lifetime (84 weeks), whereas 
CMVMJD94 animals developed a mild motor uncoordination phenotype 
starting at 16 weeks of age. Interestingly, CMVMJD135 transgenic animals 
developed a more aggressive motor uncoordination phenotype along with 
other neurological features such as gait impairment, body balance deficit, 
loss of limb clasping, grasping and muscular tonus. Immunohistochemistry 
revealed that ataxin-3 is located mainly in the perinuclear regions of 
neurons forming small-punctate aggregates in CMVMJD94 and 
CMVMJD135 mouse brains. In addition, in the CMVMJD135 model we 
observed large intranuclear inclusions, although not exclusively in the 
affected areas.  
In summary, we have created two mouse models for MJD with different 
pathological and phenotypical features that may model different stages of 
the disease, which may contribute substantially for the understanding of 
MJD pathogenesis. The CMVMJD135 model is currently being used for 
therapeutical trials targeting different molecular pathways that might be 
involved in the disease, including autophagy.  
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Cytoplasmic dynein is a minus-end directed microtubule motor protein 
responsible for many cellular functions including fast retrograde axonal 
transport. The Loa dynein mutant mouse was initially identified to develop 
progressive lower motor neuron degeneration similar to ALS; however, 
recent reports have found that these mice undergo severe sensory neuron 
loss. The Loa mutation is located within the tail domain of the dynein heavy 
chain, but no effects have been reported on dynein function. To test for 
defects in dynein function, we purified the motor protein from stockpiled 
brains of wild type and Loa/+ mice. The purified mutant and wild type 
preparations were indistinguishable in composition. Although basal ATPase 
activity was the same for both preparations of dynein, the mutant dynein 
exhibited a dramatic increase in the Km, but a normal Vmax, suggesting a 
decreased affinity for microtubules. This was confirmed by microtubule 
binding assays, which revealed decreased affinity of the mutant dynein in 
the presence, though not the absence, of ATP. We performed an extensive 
analysis of wild type and mutant dynein biochemically and at the single 
molecule level. Compared with wild type dynein, individual mutant dynein 
molecules associated with QD or polystyrene beads exhibited a 23% to 50% 
reduction in run length along microtubules due to significantly altered 
motor domain coordination. High resolution particle tracking using 
LysoTracker revealed a decrease in run length for lysosomes/late 
endosomes in mutant versus wild type hippocampal neurons, which could 
be quantitatively accounted for by computational modeling based on the 
processivity differences we had identified. These results provide the first 
indication that dynein tail mutations can affect motor activity. By impairing 
dynein’s processivity, the Loa mutation likely compromises the ability of 
mutant dynein to efficiently transport cargo along the axon, leading to 
neurodegeneration in mice. Supported by RO1GM070676, AHA0825278F, 
GM47434, and the Columbia University Motor Neuron Center. 
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Spinal muscular atrophy (SMA) is an inherited motor neuron disease caused 
by reduced levels of the survival motor neuron (SMN) protein. SMN is part 
of a macromolecular complex required for the assembly of spliceosomal 
small nuclear ribonucleoproteins (snRNPs)the essential components of the 
pre-mRNA splicing machinery. We previously showed that, in mouse 
models of SMA, snRNP assembly defects correlate with disease severity 
and cause a preferential decrease in the levels of the snRNPs that are 
responsible for splicing a rare class of introns (U12-type). However, 
whether SMN-dependent splicing defects contribute to neuromuscular 
dysfunction remains to be determined. To address this fundamental issue, 
we carried out a genome-wide analysis of the consequences of SMN 
deficiency on the U12 splicing pathway and the relevance for 
neuromuscular function in Drosophila mutants of SMN. In this model of 
SMA, low SMN levels cause synaptic dysfunction at the neuromuscular 
junction (NMJ), decrease muscle size, and impair locomotion. We found 
that SMN deficiency affects the splicing of U12 introns and that expression 
of about 40% of all U12 intron-containing genes is decreased in Drosophila 
SMN mutants. Functional analysis of these SMN target genes led to the 
identification of a novel evolutionarily conserved transmembrane protein—
which we named Stasimon—that is strongly expressed in neurons and 
essential for proper neurotransmitter release at the NMJ. Importantly, 
restoring neuronal expression of Stasimon in Drosophila mutants of SMN 
corrects synaptic dysfunction and improves muscle size and locomotion. 
These findings reveal that SMN-dependent U12 splicing events are essential 
for normal synaptic transmission in vivo and that SMN deficiency can cause 
neuromuscular dysfunction by affecting the splicing of genes critical for 
neuronal activity. 
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Neurofibrillary tangles are a hallmark of Alzheimer’s disease (AD) 
pathology. They are composed of hyperphosphorylated forms of the 
neuronal microtubule associated protein tau. Many kinases are capable of 
phosphorylating tau in vitro, but it is not clear which are important for the 
neurodegenerative process in AD. It is crucial to identify the kinases that 
regulate tau phosphorylation since they are potential therapeutic targets. 
Drosophila melanogaster is an excellent model system for studying human 
neurodegenerative diseases. Over-expression of human tau in Drosophila 
photoreceptor neurons results in neurodegeneration that bears many of the 
hallmarks of AD including presence of abnormally phosphorylated tau. 
 
We are utilising Drosophila as in vivo animal assay to identify which 
human kinases and which phosphorylation events are responsible for the 
generation of toxic forms of tau. This model could be used to identify small 
molecules that prevent the neurodegenerative process in AD. With this aim, 
several Drosophila lines over-expressing human tau in photoreceptor 
neurons were established and the ability of human kinases to modulate tau-
mediated neurodegeneration was tested. 
 
As predicted, when human GSK3β was co-expressed with human tau in the 
photoreceptor neurons increased degeneration was observed similar to that 
previously reported with the Drosophila orthologue shaggy. This 
demonstrates that human kinases are functional in living Drosophila. 
Other kinases thought to be important in tau hyperphosphorylation are now 
being investigated, including the dual-specificity tyrosine-phosphorylation 
regulated kinase 1A (DYRK1A). In vitro DYRK1A phosphorylates only a 
small number of residues of tau. Since it is also highly expressed in Down 
syndrome patients as well as in AD brains, DYRK1A might play a potential 
important role in conferring tau toxicity during pathogenesis. 
 
We show here that both DYRK1A and its Drosophila orthologue, 
minibrain, enhance the toxicity of tau in the fly eye. We are currently 
investigating which are the major phosphorylation events responsible for 
generating toxic forms of tau. 
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The ability to generate subtype-specific populations of neurons from human 
embryonic stem cells (hESCs) and induced pluripotent stem cells (hIPSCs) 
presents an unrivalled model for the study of neurodegenerative disease in 
human cells. Neurodegenerative diseases often exhibit loss of region-
specific neurons making the generation of neuronal subtypes key to the 
study of underlying mechanisms. Using whole-cell patch-clamp, hESC-
derived neurons expressing regional markers for anterior, posterior, 
midbrain or motor neuron identity as well as hIPSC-derived motor neurons 
have been electrophysiologically analysed. Neurons from all populations 
fired TTX-sensitive action potentials in response to current injection. In 
addition, neurons displayed agonist-evoked currents indicating the 
expression of GABA, NMDA and AMPA type receptors. Finally, 
spontaneous excitatory post-synaptic currents were observed in older 
cultures signifying the capacity of these cells to form functional networks. 
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Axonal degeneration is a main contributor to disability in progressive 
neurodegerative diseases associated to oxidative stress. Here we establish a 
direct link between oxidative stress and axonal damage in a mouse model of 
X-adrenoleukodystrophy, a lethal disease caused by loss of function of the 
ABCD1 peroxisomal transporter of very long-chain fatty acids (VLCFA). 
The mouse model for X-ALD exhibits a late-onset locomotor disability and 
axonal degeneration in spinal cords. We deliver conceptual proof of the 
capability of the antioxidants N-acetyl-cysteine, lipoic acid and alpha-
tocopherol to scavenge VLCFA-dependent ROS generation. In a preclinical 
setting, the cocktail reversed: i) oxidative stress and lesions to proteins, ii) 
immunohistological signs of axonal degeneration and iii) locomotor 
impairment in bar cross and treadmill tests. These results warrant translation 
into clinical trials for X-adrenoleukodystrophy patients, and invite 
assessment of antioxidant strategies in other diseases with axonal 
degeneration in which oxidative damage might play a role. 
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Machado-Joseph disease (MJD) is an autosomal dominant 
neurodegenerative disorder, with a mean onset in adulthood (around 40 
years). Its causative mutation consists in an expansion of a (CAG)n tract in 
the coding region of the ATXN3 gene (14q32.1), which encodes for ataxin-
3. The inverse correlation between the number of CAG repeats in the 
expanded alleles and the age at onset accounts for only around 50 to 70% of 
onset variance, the remaining variation being dependent on factors currently 
unknown. Although ubiquitously expressed, differential levels of ataxin-3 
may constitute one of the factors responsible for the clinical heterogeneity 
observed in MJD. The main goal of this work was to analyze the extent of 
the genetic variation upstream of the ATXN3 start codon, in its core 
promoter, as well as in its 5’ untranslated region (UTR), which possibly 
influence gene expression levels and, therefore, may ultimately be 
associated with variance in the MJD’s age at onset. Sequence analysis was 
performed in 59 MJD patients and 59 controls. The ATXN3 core promoter 
region was shown to be highly conserved, with no polymorphisms being 
observed in the 236 analyzed chromosomes. In the 5’-UTR, one SNP (c.-
31C>T) was found, both in MJD patients and controls. This SNP falls in a 
region which may affect CMYB transcription factor binding, as well as 
translation regulation and, therefore, may have a putative functional role. 
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Alzheimer’s disease (AD) is a complex disease process in which pathology 
plays a vital role in its diagnosis. For the past few years, neuroimaging, a 
non invasive in vivo procedure, has played an important role in the research 
and diagnosis of AD. Many studies have shown atrophy of the hippocampus 
(Hp) as well as the entorhinal cortex (EC) which also atrophies very early in 
the disease process. AD pathology starts in neither of those areas but in a 
transitional area called the transentorhinal area (TER) from which it spreads 
to the EC, Hp and the temporal isocortex and then throughout the entire 
brain. The diaschisis theory postulates that breaking neuronal ties between 
regions could also produce temporary impairments of function. Applying 
this theory on AD would show the altered white matter tracts in AD are due 
to their disrupted connections with the atrophied hippocampal formation. 
This study aims to compare the associations between the gray matter 
volumes and rates of atrophy EC, Hp, and TER with cingulum bundle in 
controls, amnestic MCI, and AD patients. The second aim of this study is, 
to determine the correlations of those three gray matter areas with memory 
scores specific for the EC and Hp such as immediate free recall and delayed 
free recall respectively. In this project, our hypothesis is that the TER is a 
key to a memory network and once disrupted affects the whole network. 
Therefore, correlating TER volumetric measurements with the other areas 
might be of particular interest. Also, using the diaschisis concept, the 
relation between gray matter atrophy and its associated white matter is 
evaluated with an expected positive correlation. Manual segmentation of the 
three areas Hp, EC, and TER is performed to obtain regions of interest and 
the volume measurements are extracted. A positive correlation is also 
expected between gray matter measurements and memory scores of the 
neuropsychological tests. Finally, TER atrophy is expected to correlate 
more with EC atrophy than with Hp.  
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The amyloid beta (Aβ) hypothesis proposes that increased levels of the Aβ 
protein and its consequent assembly and aggregation from soluble to 
oligomers and into fibrillar amyloid plaques in the brain are the primary 
events driving Alzheimer's disease (AD). The early soluble assemblies of 
Aβ, may be more pathogenic than the fibrillar structures. We and others 
have identified a key role of aromatic residues in the molecular recognition 
and self-assembly leading to the formation of various amyloid assemblies. 
Aromatic interactions are believed to provide selectivity as well as stability 
to the interacting molecules. Our strategy is to use small aromatic molecules 
that would bind the aromatic residues of the Aβ monomers thereby inhibit 
the early steps of the molecular recognition and structural transition of the 
monomers which lead to the formation of the toxic amyloid species. 
Quinones have been known as inhibitors of various metabolic pathways in 
the cell, serve as antibacterial, anti-viral, and anti-cancer agents and 
furthermore were shown to inhibitor several amyloidogenic peptides. We 
have synthesized a series of N-linked tryptophan-modified quinones and 
screened them for anti-Aβ activity. Two compounds, NQTrp and Cl-
NQTrp, were most effective. They inhibit Aβ oligomerization and 
fibrillization in vitro and reduce the cytotoxic effect of Aβ oligomers 
towards cultured cells. NMR spectroscopy and molecular dynamics 
simulations provide a mechanistic basis for the activity of these compounds. 
When fed to Drosophila expressing Aβ in their nervous system, these 
compounds alleviated their Alzheimer's-related symptoms which include 
defective locomotion and reduced life span, while having no effect on 
control flies. Injection of Cl-NQTrp to 5xFAD transgenic AD mice resulted 
in significant improvement of their cognitive behavior, dramatic reduction 
in the level of both soluble and insoluble Aβ in their brain extracts and 
marked decrease in Aβ deposition in their brains. Thus, these Trp-modified 
naphthoquinones may be useful candidates as disease-modifying drugs for 
AD. 
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TDP-43 is an RNA binding protein that has recently been implicated in both 
Amyotropic lateral sclerosis (ALS) and Frontotemporal lobar degeneration 
with ubiquitin positive inclusions (FTLD-U). These two diseases affect 
different classes of neurons, yet share TDP-43 as the likely causative agent 
and make up a spectrum of disorders called TDP-43 proteinopathies. 
Modeling of TDP-43 proteinopathy is critical to gain an understanding of 
TDP-43’s normal function, as well as its pathological mechanisms. We 
have used a recently developed yeast model of TDP-43 proteinopathy that 
recapitulates several relevant disease features to screen for compounds that 
rescue cellular toxicity. Yeast offers a tremendous opportunity for high 
throughput chemical screening where a simple return to growth identifies 
hit compounds. Such molecules are being employed as biological probes to 
further interrogate TDP-43 pathology in both yeast and neuronal models. 
The screen identified a number of small molecules, four of which are 
currently being investigated for modes of action in both yeast and neuronal 
systems. Surprisingly, identified compounds frequently display a broad 
protection over multiple yeast models – including α-synuclein and PolyQ – 
suggesting they may target fundamental protective pathways. The 
identification of compounds that rescue different models suggests that a 
particular druggable target may be exploited to potentially treat multiple 
diseases. 
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The appearance of protein aggregates in neurons is a common hallmark of many 
late-onset neurodegenerative disorders. In Huntington’s disease, a trinucleotide-
expansion in the disease gene leads to an enlarged glutamine-stretch in the 
Huntingtin-protein and its subsequent misfolding and oligomerization. How 
microscopically visible inclusions are formed via misfolding intermediates is 
incompletely understood. About 60% of the variation in the age of disease onset 
can be predicted by the length of the glutamine stretch. The other 40% is caused 
by environmental factors and other genetic factors. A better understanding of 
the aggregation-process could provide new means of therapeutic intervention. 
 
In our lab, we use a small animal model for polyglutamine aggregation (the 
nematode Caenorhabditis elegans) to search for genetic modifiers of protein 
aggregation. By a genome-wide RNA-interference (RNAi)-screen (1) and 
chemical mutagenesis of polyglutamine-expressing worms (2), almost 200 
genes were identified that positively or negatively affect protein aggregation. 
These genes included known regulators of protein aggregation, genes not 
previously linked to aggregation, and genes with unknown function. 
 
To extrapolate these results to human disease, we examined the human 
homologs of these genes for a possible role as a genetic modifier of 
Huntington’s disease. We designed siRNA-sequences for inhibition of protein 
expression, and used a polyglutamine-reporter system in cultured human cells to 
visualize aggregation. In addition to established modifiers of protein 
aggregation in mammalian cells (molecular chaperones, the proteasome 
system), also a number of genes that were not previously linked to this process 
showed to be involved in aggregation of mutant Huntingtin. We will report 
about these genes and their role in protein aggregation in more detail. 
 
(1) Nollen EA, Garcia SM, van Haaften G, Kim S, Chavez A, Morimoto RI, Plasterk 
RH. (2004) Genome-wide RNA interference screen identifies previously 
undescribed regulators of polyglutamine aggregation Proc Natl Acad Sci U S A. Apr 
27;101(17):6403-8.  
 
(2) van Ham TJ, Holmberg MA, van der Goot AT, Teuling E, Garcia-Arencibia M, 
Kim HE, Du D, Thijssen KL, Wiersma M, Burggraaff R, van Bergeijk P, van 
Rheenen J, Jerre van Veluw G, Hofstra RM, Rubinsztein DC, Nollen EA.(2010) 
Identification of MOAG-4/SERF as a regulator of age-related proteotoxicity. Cell. 
142(4):601-12. 
 62 
SH3 DOMAINS FROM A SUBSET OF BAR-PROTEINS DEFINE A 
NOVEL UBL-BINDING MODULE AND IMPLICATE PARKIN IN 
SYNAPTIC UBIQUITINATION. 
 
Jean-Francois Trempe1,2, Carol Xiuqing Chen1, Karl Grenier1, Peter S 
McPherson1, Kalle Gehring2, Edward A Fon1  
 
1Montreal Neurological Institute, McGill University, Department of 
Neurology & Neurosurgery, Montreal, H3A 2B4, Canada, 2McGill 
University, Department of Biochemistry, Montreal, H3G 0B1, Canada 
 
Parkin, a gene responsible for a familial form of Parkinson’s disease, 
encodes a RING-type E3 ubiquitin-ligase with an N-terminal ubiquitin-like 
domain (Ubl). By virtue of its similarity to ubiquitin, the parkin Ubl can 
interact with ubiquitin-binding domains (UBDs). However, almost nothing 
is known about the selectivity of parkin Ubl towards UBDs or its role in 
recruiting ubiquitination substrates. We report here that the SH3 domains of 
endophilin-A, syndapin and amphiphysin-II interact with parkin Ubl but not 
with ubiquitin or other Ubl's. These endocytotic SH3 proteins all have a 
BAR domain that binds and induces curvature in lipid bilayers. In synapses, 
parkin associates with endophilin-A1 in a phosphorylation-dependent 
manner and ubiquitinates SH3-associated proteins. The structure of the 
endophilin-A1 SH3 in complex with the Ubl was determined using NMR 
spectroscopy and showed that the Ubl C-terminal PxRK73-76 motif, which is 
unique to parkin, folds upon binding the SH3 domain. This allows Arg75 to 
interact with an acidic loop specific to endophilin-A SH3, thus explaining 
the selectivity of the interaction. The Ubl binds the same SH3 surface as 
proline-rich domains (PRDs), effectively competing with the dynamin and 
synaptojanin PRDs. Thus our work establishes the SH3 domain as a novel 
Ubl-binding domain and implicates endophilin-A for the first time in 
synaptic ubiquitination and Parkinson’s disease. Future studies will aim at 
identifying the ubiquitination substrates of parkin in the context of 
endophilin-A recruitment and the role this interaction might play in the 
regulation of vesicular transport. 
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Background: There are currently no robust biomarkers to predict Parkinson 
disease (PD) progression, or to correlate with development of cognitive 
impairment in PD. In recent investigation, complement 3 (C3), factor H 
(FH), as well as amyloid beta peptide 1-42 (Aβ1-42), have been weakly 
associated with PD motor disability and/or the development of cognitive 
impairment in PD.  
 
Methods: Re-analying C3, FH and Aβ1-42 in cerebrospinal fluid (CSF) 
from a well-characterized cohort of PD patients at various stages as 
determined by unified Parkinson’s disease rating scale (UPDRS) motor 
scores and cognitive impairment states.  
 
Findings: The C3/Aβ1-42 and FH/Aβ1-42 ratios not only correlated with 
PD severity, staged by UPDRS score but also aided in distinguishing PD 
with dementia (PD-D) from PD with no cognitive impairment (PD-NCI), 
and PD with cognitive impairment but no dementia (PD-CIND).  
 
Interpretation: Though further validation is needed, these data suggested 
that component activation and a decrease in CSF Aβ1-42 are independent 
processes, and a combination of two markers might provide an effective 
panel of markers that could potentially useful in monitoring PD progression, 
including the development of PD dementia.  
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Parkinson’s disease (PD) is the second most common neurological disorder, 
affecting over 10 million people worldwide. PD patients suffer from a 
variety of symptoms including decreased olfactory acuity, tremor, and 
ultimately bradykinesia. Mutations in leucine-rich repeat kinase 2 (LRRK2) 
have been linked to both familial and sporadic PD, however the function of 
LRRK2 remains to be elucidated. Here we identify and characterize a 
LRRK2 autophosphorylation site that can be detected in cells and in 
transgenic mouse models. Importantly, LRRK2 mutations associated with 
PD modulate this autophosphorylation. This discovery offers a promising 
tool to identify LRRK2 inhibitors in cell-based assays and a potential 
biomarker for monitoring LRRK2 kinase activity in vivo. 
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Telomere repeat-binding factor 2 (TRF2) is essential for stabilizing the ends 
of chromosomes in dividing cells. However, we recently reported that TRF2 
interacts with the transcriptional silencer REST at non-telomeric sites to 
regulate the expression of neuron-specific genes in neural progenitor and 
tumor cells. Here we identify a neuron-specific TRF2 alternative splicing 
isoform, TRF2-short (Sα) with a truncated C-terminus lacking Myb DNA 
binding domain and nuclear localization signal domains, and containing a 
novel nuclear export signal. A molecular switch from TRF2 to TRF2-Sα 
expression occurs during brain development coincident with the transition 
from proliferating neuronal precursors to mature postmitotic neurons. 
Unlike TRF2 which is concentrated in the nucleus of proliferating neural 
progenitor cells, TRF2-Sα is located in the cytoplasm where it binds REST. 
The association between TRF2-Sα and REST arises coincidentally with the 
maturation of Cajal-Retzius cells and pyramidal neurons in the developing 
neocortex. Overexpression of TRF2-Sα prevents nuclear accumulation of 
REST. Exposure cortical neurons to the glutamate receptor agonist kainate 
disrupts the interaction of TRF2-Sα with REST resulting in the nuclear 
translocation of REST and the repression of a subset of neuronal genes 
critical for neurite growth, neuron survival and synaptic plasticity. 
Overexpression of TRF2-Sα prevents nuclear translocation of REST and 
maintains the expression of neuronal plasticity genes. Our findings reveal a 
novel TRF2 isoform that serves a special function in the maintenance and 
modification of the mature differentiated state of neurons under adverse 
conditions such as excitotoxic stress. 
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BACE1 cleaves the amyloid precursor protein (APP) at Met671-Asp672 (β-
site) to release the amino-terminus of the amyloid peptide Aβ. A secondary 
cleavage site of BACE1, at Tyr681-Glu682 (β’-site) is also known to occur 
in APP, but the quantitative importance as well as the functional 
significance of this cleavage remains elusive. A novel APP mutation, 
E682K, located at the β’-site, was identified in a patient with early-onset 
Alzheimer’s disease (AD). In neurons expressing wild-type human APP, β’-
site cleavage was found to be a relatively abundant event. The E682K 
mutation blocked the β’-site cleavage and shifted β-secretase cleavage of 
APP to the canonical β-site, causing increased generation of Aβ1-40/42, and 
explaining the pathogenic effect of the E682K mutation. Our work shows 
that processing at the β’-site is a major processing event of human APP in 
neurons and that β’-site cleavage has a ‘protective effect’ in APP 
metabolism. Disruption of the balance between β-site and β’-site cleavage 
by mutations or other effects will enhance the amyloidogenic processing of 
APP and may consequentially lead to AD, which should be taken into 
account when developing BACE-inhibitors. 
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The identification of genes underlying rare familial forms of amyotrophic 
lateral sclerosis (ALS) has provided fundamental insights into the 
pathogenesis of motor neuron degeneration, and has directly lead to animal 
models of the disease, as well as the promise of targeted therapeutics. Thus, 
it is not surprising that the discovery of new ALS genes is of great interest 
to the field.  
 
Finland is an ideal location for performing genetics studies of ALS, because 
it has one of the highest incidences of the disease in the world, and because 
the population is known to be remarkably genetically homogeneous. To 
exploit this, we performed a genome wide association study of ALS in 
Finland to determine the genetic variants underlying disease in this 
population. Analysis revealed two highly significant association peaks in 
our GWAS, one located on chromosome 21 near the SOD1 gene, which is 
known to have a particularly high prevalence in the Finnish population, the 
other located on chromosome 9p21. Together, these two loci account for 
nearly the entire increased incidence of ALS in Finland, and represent the 
most significant “hit” reported to date in genome-wide association studies 
of this fatal neurodegenerative disease. 
 
The next stage in the genetic dissection of ALS will be the rapid 
identification of mutations underlying familial disease using exome 
sequencing. This method allows us to enrich DNA samples for the regions 
of the genome that contain protein-coding exons, which is then sequenced 
using second-generation sequencing. The power of exome sequencing has 
already been demonstrated for rare monogenic disorders; what these studies 
elegantly show is that the process of identifying the underlying gene 
mutation in single gene diseases can now be performed in less than a 
month, as opposed to the years that a linkage and positional cloning project 
has traditionally taken. We will present the results of our exome sequencing 
of ALS families.  
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Mutations in two related RNA-binding proteins, TDP-43 and FUS/TLS, 
have been linked to amyotrophic lateral sclerosis (ALS). We have been 
using yeast to define mechanisms of TDP-43 and FUS toxicity and to 
identify genetic modifiers. Using this approach, we identified the yeast 
homolog of human ataxin 2 as a potent modifier of TDP-43 toxicity. Ataxin 
2 also mitigated toxicity of TDP-43 in Drosophila and the proteins 
interacted with each other in an RNA-dependent manner. Given these 
strong genetic and physical interactions between TDP-43 and ataxin 2, we 
analyzed the ataxin 2 gene for mutations in ALS patients. Ataxin 2 is a 
polyglutamine (polyQ) protein and long expansions of the polyQ repeat 
(>34 Qs) cause spinocerebellar ataxia type 2 (SCA2). We identified 
intermediate-length polyQ (27-33 Qs) expansions in ataxin 2 as a common 
genetic risk factor for ALS. This discovery underscores the extraordinary 
power of simple model systems like yeast and fly for uncovering novel 
insights into even complicated human diseases. Building on these studies, 
we have recently used yeast to explore the hypothesis that additional human 
RNA binding proteins, like FUS and TDP-43, might contribute to ALS. We 
screened all human RNA recognition motif (RRM)-containing proteins in 
yeast and identified 35 that aggregated and were toxic (including FUS and 
TDP-43). We are analyzing these genes for mutations in ALS patients and 
have recently identified several missense variants in two of the genes in 
ALS patients that are not in >5,500 healthy controls. We propose that TDP-
43 and FUS might be the tip of an iceberg and many more aggregation-
prone RNA binding proteins could contribute to ALS. 
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The abnormal deposition of the protein fragment Aβ can be induced in Aβ-
precursor protein (APP)-transgenic mice and rats by the intracerebral 
injection of brain extracts that are rich in aggregated Aβ. To assess potential 
similarities of this process with the propagation of prions in vivo, our 
laboratory and that of Mathias Jucker in Tübingen undertook a series of 
experiments that have shown that: 1) the seeding extract is effective only if 
it contains sufficient quantities of misfolded Aβ; 2) Aβ-rich brain extracts 
seed effectively whether the source of the extract is a human, aged monkey 
or genetically modified mouse; 3) the induction of Aβ aggregation by 
extracts from transgenic mice indicates that the phenomenon is not due to 
human-specific factors or a cross-species immune reaction; 4) the induction 
of Aβ deposition requires that the host generate human-sequence Aβ; 5) 
denaturation of the extract or specific immunoneutralization of Aβ inhibits 
seeding; 6) the seeded deposits appear only after a lag period, the length of 
which is governed by both the seed and the host; 7) Aβ seeds can spread 
from one brain region to another, possibly in part due to axonal transport; 
and 8) Aβ deposition can be seeded in an APP-transgenic rat model that 
normally does not develop Aβ-lesions, at least up until 30 months of age. 
Recent studies from the Jucker laboratory have shown that cerebral Aβ-
amyloidosis can be seeded by the intraperitoneal infusion of Aβ-rich brain 
extract, indicating that the seed can be conveyed from the periphery to the 
brain. We are currently investigating the ability of heterogeneous agents to 
induce Aβ deposition, as well as putative strain-like variations in the 
pathogenicity of aggregated Aβ. Acknowledgments: Key collaborators on 
these studies include Mathias Jucker and Yvonne Eisele (U. Tübingen), 
Rebecca Rosen, Jeromy Dooyema, Amarallys Cintron, Eric Heuer, Brian 
Ciliax, Jason Fritz, Ranjita Betarbet and James Lah (Emory U.), and Harry 
LeVine III (U. Kentucky). Supported by NIH RR-00165, NIH 
P50AG025688 and the CART Foundation. 
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Axon degeneration is a hallmark of both pruning during nervous system 
development and neurodegenerative disease. The molecular mechanisms 
regulating this active process are just beginning to be understood. In order 
to discover additional pathways regulating axon degeneration we conducted 
an unbiased small molecule screen and have identified modulators of 
various pathways that block axon degeneration following growth factor 
withdrawal. Notably, a number of kinases where identified as mediators of 
axon degeneration, and further mechanistic studies localized the function of 
distinct kinases to either the axonal or cell body compartments. Further 
investigation of these pathways in axon degeneration-specific assays led us 
to an unexpected finding: glycogen synthase kinase-3 (GSK-3) is a key 
regulator of a genetic axon degeneration program acting specifically in the 
cell body to regulate distal axon degeneration. To identify potential GSK-3-
regulated axon degeneration genes, we performed time course microarray 
analysis on neurons selectively undergoing axon loss, with or without GSK-
3 inhibition. Two candidate genes were identified - tbx6, a transcription 
factor, and dleu2, a long noncoding RNA. Consistent with our model, 
siRNA knockdown of tbx6 or dleu2 reduced axon degeneration in vitro. 
Additionally, these genes are both enriched in the hippocampus of clinical 
Alzheimer’s disease samples, indicating that our proposed axon 
degeneration program may be active in human disease. 
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Alzheimer’s disease (AD) is characterized by the accumulation of 
extracellular amyloid-β (Aβ) plaques and intracellular tangles. These 
disease hallmarks are accompanied by a strong neuro-inflammatory 
component including, but not limited to, activation of the complement 
system. Our lab and others have previously shown that inhibition of the 
complement system by overexpression of the endogenous C3 convertase 
inhibitor Crry or by deletion of the major complement component C3 leads 
to increased amyloid pathology and neurodegeneration. Our goal is to 
identify which receptors mediate this effect.  
C3 and its cleavage products can be recognized by complement receptors 1 
(CR1), 2 (CR2) and 3 (CR3). These receptors display differential 
expression patterns. CR1 is expressed on leukocytes, monocytes and B-
cells, while CR2 is commonly described on B-cells. CR3, on the other hand, 
is expressed mainly on macrophages and microglia. In mice CR1 and CR2 
are splice variants of the same gene, therefore deletion of the gene locus 
results in loss of both receptors. To identify the role of these receptors on 
cerebral amyloidosis we crossed mice lacking CR1/2 or CR3 with human 
amyloid precursor protein (APP) transgenic mice harboring the familial AD 
associated Swedish (KM670/671NL) and London (V717I) mutations.  
Mice lacking and expressing CR3 were aged to 1, 3 and 12 months of age. 
Interestingly, analysis of mice at the pre-deposition ages (1 and 3 months) 
did not show changes in Aβ levels in Cortex or Hippocampus. In agreement 
with these findings we also did not observe any differences in the total 
number of microglia (Iba-1) or the number of activated microglia (CD68) in 
the brains of these animals. The analysis of the 12 months cohort is 
ongoing. In contrast, mice lacking CR1/2 display a significant increase in 
soluble Aβ at pre-deposition age (4-5 months) in both Cortex and 
Hippocampus. Unfortunately, this genetic deletion is associated with high 
lethality in APP trangenic mice and therefore we could not investigate the 
effect in older animals.  
Surprisingly, our preliminary data shows a stronger effect of deletion of the 
more peripheral expressed CR1/2 than that of the microglial receptor CR3, 
at least at pre-deposition ages.  
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Spinocerebellar ataxia type 1 (SCA1) is a fatal autosomal dominant 
neurodegenerative disorder caused by expansion of a polyglutamine tract in 
ataxin-1 (ATXN1). Phosphorylation of the SCA1 encoded protein ATXN1 
at Ser 776 modulates disease and its interaction with other cellular proteins. 
Thus, understanding the signaling pathway that regulates ATXN1 
phosphorylation at S776 in the cerebellum is important for identifying 
targets for therapeutic development. In our previous studies, we showed that 
ATXN1 is phosphorylated in the cytoplasm and PKA is a strong candidate 
for the cerebellar S776-ATXN1 kinase. In this study, we showed that 
polyglutamine tract expansion renders S776-ATXN1 more susceptible to 
phosphorylation by PKA. In addition, we examined the dephosphorylation 
of phospho-S776-ATXN1 (pS776-ATXN1) in the cerebellum. We found 
that dephosphorylation of pS776-ATXN1 occurs in the nuclei of cerebellar 
cells, which are also the subcellular site where pS776-ATXN1 is enriched. 
Protein phosphatase 2A (PP2A), a major brain Ser/Thr phosphatase, 
interacts with and dephosphorylates pS776-ATXN1 in the cerebellum. 
Polyglutamine tract expansion seems to have no effect on 
dephosphorylation by PP2A. These results indicate that PKA and PP2A 
regulate cerebellar phosphorylation of ATXN1 at S776, thus, are target 
candidates for SCA1 therapeutic development. 
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Alzheimer’s disease (AD) is strongly influenced by inheritance and genetic 
susceptibility as evidenced by numerous family and twin studies. Over the past 
two and a half decades, our laboratory has co-discovered the three early-onset 
familial AD genes, APP, PSEN1, and PSEN2, which can carry any of >200 
fully penetrant mutations characterized by mendelian inheritance. For late-onset 
AD, the only well-established risk factor is the epsilon 4 variant of APOE, 
which increases risk by 3.7-fold in the heterozygous state and >10-fold when 
two copies are inherited. It has been estimated that 50-70% of the genetic 
variance of AD remains unexplained by the four established AD genes. We are 
engaged in two major efforts to identify the additional AD genes as part of our 
Alzheimer’s Genome Project funded by the Cure Alzheimer’s Fund. First, for 
published AD candidate genes, we have developed the AlzGene.org website, a 
comprehensive, online encyclopedia and database, which includes data on >650 
AD candidate genes and >~3000 DNA variants that have been tested for 
association with AD. For all DNA variants tested in at least four independent 
samples (~300), AlzGene.org provides meta-analyses to determine the most 
promising AD candidate genes. These studies have led to over 40 candidate AD 
genes, including APOE, that yield significant results. However, the effects of 
these variants on risk are tiny compared to APOE (.75≤O.R.≤1.25). We are 
currently exploring whether these associations are being driven by rare late-
onset AD mutations in linkage diequilibrium with the disease-associated 
common variants. We found this to be the case for the APP alpha-secretase 
gene, ADAM10, in which we discovered two rare mutations that severely 
impair ADAM10 cleavage of APP both in vitro and in transgenic mice. Second, 
in a parallel effort, we have carried out several genome-wide association studies 
on >800 well-characterized late-onset AD families (NIMH and NCRAD 
samples) using Affymetrix genotyping arrays containing either one million (6.0) 
or 500,000 (5.0) genomic single nucleotide polymorphisms (SNPs) as well as 
arrays containing 20,000 coding SNPs. We have previously reported four novel 
loci that achieved genome-wide significance (besides APOE) including a novel 
gene on chromosome 14q, GWA-14q, the ataxin 1 gene, the innate immune 
system lectin gene, CD33, and the synaptic gene, DLGAP1. Functional studies 
of the ATXN1 gene carried out both in vitro and in vivo in ATXN1 knockout 
mice show that ATXN1 can regulate Aβ levels via modulation of beta-
secretase. We will also present new data implicating Aβ as an anti-microbial 
peptide in the innate immune system. These latter data in combination with 
several novel candidate genes emanating from the Alzheimer’s Genome Project 
suggest that innate immune system in the brain may play a central role in the 
etiology and pathogenesis of AD, raising new possibilities for novel drug 
discovery. 
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SorCS1 and SorL1/SorLA/LR11 belong to the sortilin family of vacuolar 
protein sorting-10 (Vps10) domain-containing proteins. Both are genetically 
associated with Alzheimer’s disease (AD), and SORL1 expression is 
decreased in the brains of patients suffering from AD. SORCS1 is also 
genetically associated with types 1 and 2 diabetes mellitus (T1DM, T2DM). 
We have undertaken a study of the possible role(s) for SorCS1 in 
metabolism of the Alzheimer’s amyloid β peptide (Aβ) and the Aβ 
precursor protein (APP), to test the hypothesis that Sorcs1 deficiency might 
be a common genetic risk factor underlying the predisposition to AD that is 
associated with T2DM. Overexpression of SorCS1cβ-myc in cultured cells 
caused a reduction (p 0.002) in Aβ generation. Conversely, endogenous 
murine Aβ 40 and Aβ 42 levels were increased (Aβ 40, p 0.044; Aβ 42, p 
0.007) in the brains of female Sorcs1 hypomorphic mice, possibly 
paralleling the sexual dimorphism that is characteristic of the genetic 
associations of SORCS1 with AD and DM. Since SorL1 directly interacts 
with Vps35 to modulate APP metabolism, we investigated the possibility 
that SorCS1cβ-myc interacts with APP, SorL1, and/or Vps35. We readily 
recovered SorCS1:APP, SorCS1:SorL1, and SorCS1:Vps35 complexes 
from nontransgenic mouse brain. Notably, total Vps35 protein levels were 
decreased by 49% (p 0.009) and total SorL1 protein levels were decreased 
by 29% (p 0.003) in the brains of female Sorcs1 hypomorphic mice. From 
these data, we propose that dysfunction of SorCS1 may contribute to both 
the APP/Aβ disturbance underlying AD and the insulin/glucose disturbance 
underlying DM. 
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Tat activating regulatory DNA-binding protein (Tardbp or TDP-43), an 
essential metazoan DNA/RNA binding protein thought to be involved in 
RNA transcription and splicing, has been associated with the 
pathophysiology of neurodegenerative diseases. However, neither the 
physiological role of TDP-43 nor its downstream targets are well defined. 
To begin to address these issues, we employed genetic approaches to 
determine the in vivo function of TDP-43 through analysis of TDP-43 
transgenic and conditional knockout mice as well as embryonic stem (ES) 
cell model system. To date, our transgenic efforts revealed that increased 
accumulation of human TDP-43 in neurons led to formation of abnormal 
intranuclear inclusions comprised of TDP-43 and fused in 
sarcoma/translocated in liposarcoma (FUS/TLS), and massive accumulation 
of mitochondria in TDP-43-negative cytoplasmic inclusions in motor 
neurons, lack of mitochondria in motor axon terminals, and immature 
neuromuscular junctions. Moreover, whereas an elevated level of TDP-43 
disrupts the normal nuclear distribution of survival motor neuron (SMN)-
associated Gemini of coiled bodies (GEMs) in motor neurons, its absence 
prevents the formation of GEMs in the nuclei of these cells. Interestingly, 
transcriptome-wide deep sequencing analysis revealed that a decrease in 
abundance of neurofilament transcripts contributed to the reduction of 
caliber of motor axons in TDP-43 mice. In parallel, our TDP-43 knockout 
approach showed that postnatal deletion of TDP-43 in mice caused dramatic 
loss of body fat. Importantly, our high-throughput DNA sequencing 
analysis on the transcriptome of ES cells lacking TDP-43 revealed a set of 
downstream targets of TDP-43 and showed that Tbc1d1, a gene known to 
mediate leanness and linked to obesity, is down-regulated in the absence of 
TDP-43. Collectively, our results established that TDP-43 is critical for fat 
metabolism and indicated that TDP-43 participates in pathways critical for 
motor neuron physiology, including those that regulate the normal 
distributions of SMN-associated GEMs in the nucleus and mitochondria in 
the cytoplasm.  
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Mutations in the Progranulin (PGRN) gene, resulting in progranulin haplo-
insufficiency, were recently found to be a major cause for Frontotemporal 
Lobar Degeneration with TDP-43 aggregates (FTLD-TDP). PGRN encodes 
a 68.5 kDa secreted glycoprotein that has been implicated in wound healing, 
inflammation, cell survival and tumorigenesis, with its normal function in 
the central nervous system (CNS) remaining to be defined. Here, we 
examined PGRN binding to the cell surface. PGRN binds to cortical 
neurons with high affinity via its C-terminus, and unbiased expression 
cloning identifies Sortilin (Sort1) as a binding site. Sortilin binds to 
progranulin with nanomolar affinity and Sort1-/- neurons showed 
significantly reduced binding to progranulin. Furthermore, Sortilin rapidly 
endocytoses and delivers PGRN to lysosomes. Mice lacking Sortilin have 
elevations in brain and serum PGRN levels of 2.5- to 5-fold. The 50% 
PGRN decrease causative in FTLD-TDP cases is mimicked in GRN+/- 
mice, and is fully normalized by Sort1 ablation. Sortilin mediated PGRN 
endocytosis is likely to play a central role in FTLD-TDP pathophysiology. 
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Spinal Muscular Atrophy (SMA) and Friedreich's ataxia (FRDA) each have 
unique genetic causes, neuropathologies, and disease presentations. 
However, these two diseases also share some striking similarities. They are 
both autosomal recessively inherited disorders that are caused by reduced 
expression of a single protein product. SMA is the consequence of mutation 
of the survival motor neuron 1 (SMN1) gene, reduced expression of full 
length SMN transcripts arising from a duplicate gene (SMN2), and 
consequently reduced levels of SMN protein. FRDA is caused by a GAA-
CTT triplet repeat insertion in an intron of the frataxin gene that interferes 
with transcription elongation resulting in reduced amounts of the frataxin 
protein. An increase in gene expression can potentially be therapeutic since 
both SMN2 and mutant FXN would produce a native, fully functional 
protein. We are developing orally active, small molecules that can achieve 
gene expression changes and positive effects in animal models of disease. 
This presentation will summarize the pre-clinical characterization of the 
molecules and their targets and discuss issues that arise in advancing these 
experimental therapeutics through clinical development. 
Frataxin expression can be increased in patient derived cells and transgenic 
mice with an HDAC inhibitor of the benzamide structural group. These 
molecules are class I HDAC specific and selective for HDAC3. While 
HDAC inhibitors alter expression of a number of genes, the frataxin gene 
expression is increased by these compounds only in the context of the 
mutant gene containing a triplet repeat insertion. Biomarkers of frataxin 
gene and protein changes have been developed to aid in assessing drug 
effects early in clinical research. Challenges also exist in how to determine 
optimal dosing to achieve target tissue changes of frataxin expression and 
how to measure treatment effects in FA patients. 
A variety of targets are being evaluated to achieve increased expression of 
SMN protein to treat SMA including HDAC inhibitors, splicing modulators, 
and translation termination blockers. A screen for increasing SMN2 
promoter activity using production of a reporter gene product identified a 
compound that appears to result in modest increases in SMN protein and 
prolonged survival in mouse models of SMA. The protein target of these 
compounds is the mRNA cap degrading enzyme DcpS. Characterization of 
a clinical candidate in vivo provides some insight into the challenges in 
clinical development and treatment of SMA in the course of normal disease 
presentation. 
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Transactive response DNA-binding protein 43 (TDP-43) ubiquitinated 
inclusions are a hallmark feature of amyotrophic lateral sclerosis (ALS) and 
of frontotemporal lobar degeneration with ubiquitin-positive inclusions 
(FTLD-U). Mutations in TARDBP, the gene encoding TDP-43, are 
associated only with 3% of sporadic and familial ALS, yet multiple 
neurodegenerative diseases exhibit TDP-43 pathology without known 
TARDBP mutations. To investigate pathogenic pathways associated with 
TDP-43 abnormalities, we generated transgenic mice expressing modest 
levels of human TDP-43 genomic fragments encoding WT TDP-43 or ALS-
linked mutant forms of TDP-43 (A315T and G348C). The TDP-43G348C 
and TDP-43A315T transgenic mice and to a lesser extent TDP-43Wt mice 
exhibited during aging impaired learning and memory capabilities as well 
as motor dysfunction as monitored by the rotarod test. Analysis of the brain 
and spinal cord sections of the TDP-43G348C transgenic mice revealed 
ubiquitin positive TDP-43 inclusions in the cytosol of motor neurons during 
aging. Interestingly, prominent and progressive neuroinflammation was 
detected in the TDP-43 transgenic mice during aging with microgliosis and 
astrogliosis starting in the brain and later on in the spinal cord. TDP-43 
mice exhibited other features of ALS with formation of peripherin 
accumulations and abnormal peripherin RNA splicing in the CNS. One such 
neurotoxic peripherin splice variant, called Per61, was upregulated in the 
TDP-43G348C mice whereas NF-L was downregulated. Even though TDP-
43 transgenic mice do not develop paralysis and death, they exhibit many of 
the pathological changes of human ALS including TDP-43 inclusions, 
appearance of TDP-43 cleavage fragments, peripherin aggregates, NF-L 
donwregulation and neuroinflammation. Work is in progress to study why 
neuroinflammation develops in TDP-43 transgenic mice despite the absence 
of neurodegeneration. 
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The identification of ALS-causing mutations in TDP-43 and FUS/TLS, two 
RNA/DNA binding proteins, combined with TDP-43 mislocalization in 
most incidences of sporadic ALS has initiated a paradigm shift in defining 
mechanisms underlying ALS. TDP-43 has been proposed to participate in 
several steps of RNA processing including alternative splicing regulation. A 
fundamental issue is the precise role(s) of TDP-43 in RNA metabolism 
regulation and how alterations in its properties may underlie 
neurodegeneration. We have now identified brain RNA targets for TDP-43 
using cross-linking and immunoprecipitation coupled with high-throughput 
sequencing (known as HITS-CLIP or CLIP-seq). Furthermore, differences 
in adult brain mRNA levels and alternative splicing events affected by 
TDP-43 were comprehensively determined from more than two hundred 
million sequences (with a method known as RNA-seq) before and after 
antisense oligonucleotide-mediated depletion of TDP-43. A basis for 
neuronal vulnerability from TDP-43 mutation was uncovered from the RNA 
map of TDP-43 binding: TDP-43 has a predominant role in maintaining the 
abundance of brain-enriched RNA transcripts derived from genes with very 
long introns and which encode proteins involved in synaptic activity. 
Determination of the RNAs affected by TDP-43 also uncovered a broad role 
for TDP-43 in influencing splicing efficiencies of alternatively used exons 
and that TDP-43 alters expression of disease-related proteins, such as 
FUS/TLS and granulin. Lastly, TDP-43 was found to auto-regulate its own 
synthesis, providing a mechanism through which cytoplasmic aggregation 
will trigger runaway synthesis of TDP-43 that may in turn amplify the 
initiating aggregates. 
 80 
USING STEM CELLS AND REPROGRAMMING TO STUDY ALS 
 
Francesco P Di Giorgio1,2,3, Gabriella Boulting1,2,3, Evangelos Kiskinis3, 
Alexandra S de Boer3, Sam Bobrowicz 3, Kevin C Eggan1,2,3  
 
1Harvard Stem Cell Institute, Cambridge, MA, 02138, 2Stowers Medical 
Institute, Kansas City, MO, 64110, 3Harvard University, Stem Cell & 
Regenerative Biology, Cambridge, MA, 02138 
 
Di Giorgio FP¹, Boulting GL¹²³, Kiskinis E³, De Boer S³, Bobrowicz S³, 
Eggan KC¹²³. 
The Harvard Stem Cell Institute¹, The Stowers Medical Institute², 
Department of Stem Cell and Regenerative Biology³, Cambridge, MA 
02138, USA. 
 
It has been proposed that human embryonic stem cells could be used to 
provide an inexhaustible supply of differentiated cell types for the study of 
disease processes. Although methods for differentiating embryonic stem 
cells into specific cell types have become increasingly sophisticated, the 
utility of the resulting cells for modeling disease has not been determined. 
We have asked whether specific neuronal subtypes produced from human 
embryonic stem cells and induced pluripotent stem cells can be used to 
investigate the mechanisms leading to neural degeneration in amyotrophic 
lateral sclerosis (ALS). We show that human spinal motor neurons, but not 
interneurons, are selectively sensitive to the toxic effect of glial cells 
carrying an ALS-causing mutation in the SOD1 gene. Our findings 
demonstrate the relevance of these non-cell-autonomous effects to human 
motor neurons and more broadly demonstrate the utility of human 
embryonic stem cells for studying disease and identifying potential 
therapeutics.  
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Amyotrophic Lateral Sclerosis (ALS) is a result of the selective dysfunction 
and progressive degeneration of motor neurons. Although the underlying 
disease mechanisms remain unknown, recent in vivo and cell culture 
experiments have implicated glial cells in motor neuron degeneration in 
ALS.  
We have made use of the SOD1 mouse model of ALS to study the effect of 
glial cells bearing the mutant SOD1 transgene on motor neuron viability in 
cell culture. Specifically, we have studied the gene expression profiles of 
co-cultured mouse embryonic stem (ES) cell derived motor neurons and 
primary glia using the Illumina deep sequencing platform (RNAseq). In this 
study, we vary both the genotype of the motor neurons and glia, as well as 
time in culture as a means of examining both cell autonomous and non-cell 
autonomous effects of the mutant transgene. In addition, we carry out 
parallel studies with spinal cord samples from mutant and wildtype SOD1 
mice, and compare both the in vivo and in vitro derived data sets with laser 
capture microdissection studies of both the ALS mouse model and human 
ALS patient samples.  
We have detected significant cell autonomous and non-autonomous changes 
in gene expression in both motor neurons and glia, indicating that the two 
cell types profoundly affect each other’s gene expression. In addition, we 
find a remarkable concordance between the different data sets mentioned 
above, thus validating the in vitro approach. We are currently analyzing 
these data sets to identify changes in the expression of specific genes and 
signaling pathways that may contribute to motor neuron degeneration in 
ALS. 
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Alexander disease (AxD) is a fatal neurodegenerative disease caused by 
dominant mutations in the astrocyte intermediate filament protein glial 
fibrillary acidic protein (GFAP). The disease is characterized by 
cytoplasmic protein inclusions, called Rosenthal fibers (RFs), within the 
cell bodies and processes of astrocytes. Accumulation of total GFAP above 
an undefined toxic threshold, and activation of multiple stress pathways, are 
considered central elements in pathogenesis. However, some aspects of the 
stress response may be beneficial. Nrf2 is a transcription factor which binds 
to and activates a consensus antioxidant response element found in the 
promoter regions of multiple genes thought essential for protection against 
oxidative stress. Although Nrf2 is naturally elevated in AxD, we sought to 
test whether further elevation of Nrf2 expression in astrocytes above its 
naturally occurring levels would decrease GFAP and RFs in mouse models 
of AxD. We crossed transgenic mice over-expressing Nrf2 under the control 
of the GFAP promoter with knock-in mice expressing the R236H point 
mutation of GFAP (comparable to the R239H mutation in human GFAP). 
We found that Nrf2 over-expression in GFAP-R236H mice decreased 
GFAP protein levels in all six brain regions examined (olfactory bulb, 
hippocampus, cerebral cortex including underlying white matter, brain 
stem, cerebellum, and cervical spinal cord) at post-natal day 11 (P11) and 
12 weeks of age, as measured by GFAP ELISA. Lower levels of GFAP 
were accompanied by fewer RFs in olfactory bulb and cortex at 12 weeks of 
age. Nrf2 over-expression also increased the body weight of GFAP-R236H 
mice to near wild-type levels. In contrast to GFAP-R236H mice, crossing 
Nrf2 over-expressing mice with transgenic mice over-expressing human 
wild-type GFAP (a more severe but less accurate model of AxD) led to an 
increase in GFAP and RFs, especially in brainstem, followed by early death 
between P11 and P18. Preliminary observations suggest death may be due 
to seizures. Our results suggest that pharmacological or genetic 
interventions aimed at increasing Nrf2 levels and activity may be a 
promising therapy for AxD, but that activation of stress pathways requires 
careful calibration to the degree of preexisting pathology. 
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Mutations in Parkin/Park2, PINK1/Park6, and DJ-1/Park7 lead to 
autosomal recessive forms of Parkinson’s disease. Deletions of these genes 
present with mitochondrial dysfunction in many model systems such as 
zebrafish, mammalian cells, and Drosophila. Genetic analysis has shown 
interactions between the three genes in Drosophila. To further elucidate 
mechanisms that lead to pink1 associated mitochondrial dysfunction and 
degeneration, we used Drosophila mutant for pink1 and performed an 
upregulation screen to identify suppressors of the muscle degeneration and 
germ line sterility defects found in the pink1 mutants. One gene that 
consistently rescued pink1 toxicity in the fly was levy, a nuclear encoded 
component of cytochrome c oxidase of the electron transport chain. 
Interestingly, levy null mutant flies display brain degeneration and early 
death, suggesting that this gene plays an important role in normal brain 
structure and function. We found that not only did upregulation of levy 
suppress pink1 toxicity, but also reduced activity of levy rescued pink1 
toxicity. In addition to mitigating apoptosis of muscle and abnormal wing 
posture of pink1 mutants, flies with reduced levy activity also show a 
dramatic increase in mitochondrial complex II and complex IV activities, 
along with rescue of lifespan. Moreover, normal wildtype flies with reduced 
levy also lived longer. These findings suggest that complex IV may be a 
potential target for mitigating toxicity of neurodegenerative disease genes 
and for promoting healthier lifespan. 
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A central challenge in the development of in vitro models for Huntington's 
disease (HD) is the recapitulation of the neuronal and glial complexity and 
interactions involved in the in vivo pathogenesis of the disease. Creating a 
primary neuronal-based model that is also amenable to moderate or high-
throughput drug screening presents an even greater challenge.  
 
Here we describe a mixed primary co-culture screening platform, including 
cortical and striatal neurons as well as glial cells, in which a tamoxifen-
inducible Cre-lox system (Matsuda and Cepko, PNAS, 2007) is used to drive 
expression of a mutant HD-exon1 sequence encoding 73 glutamines 
(HttN90Q73). Co-cultures are co-transfected with a CRE driver, a loxP-
HttN90Q73 sequence and fluorescent protein reporters, and then allowed to 
mature for one week before inducing HttN90Q73 expression with tamoxifen. 
Transfected neurons subsequently undergo progressive neurodegeneration over 
the second week in culture, which is rescuable by neuroprotective compounds 
previously characterized in in vitro and in HD animal models. An important 
feature of this screening assay is that different fluorescent reporters are used for 
striatal vs. cortical neurons, allowing their analysis as separate populations 
within these mixed and dense co-cultures using automated, high-content image 
analysis on the Cellomics ArrayScan VTI platform. 
 
A key advantage of this new inducible co-culture model is that mutant Htt 
expression can be delayed until phenotypic differentiation of cortical and striatal 
neurons has progressed significantly further than in typical primary culture 
assays, following maturation of striatal and cortical phenotypes and after 
profuse, functional synaptic connectivity has been established. This approach 
thereby allows the use of more complex phenotypic endpoints, including image-
based, high-content analysis of HD-related changes in dendritic 
morphology/extent and in synaptic numbers and function, and TR-FRET-based, 
high-throughput assays for levels and processing of soluble vs. 
oligomeric/aggregated Htt protein in the context of mature neurons and 
neuronal circuits. 
 
The development of such high-content and high-throughput assay endpoints in 
more mature and complex neuronal culture platforms should support the 
identification of drug and drug target candidates with more predictive value for 
clinical benefit early in the drug discovery process. 
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Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal 
neurodegenerative disorder for which there is no cure. Burgeoning evidence 
suggests that RNA binding proteins play a critical role in pathogenesis. The 
RNA binding proteins, TDP-43 and FUS, are principal components of 
cytoplasmic inclusions found in the degenerating motor neurons of ALS 
patients. Moreover, mutations in TDP-43 and FUS are linked to familial and 
sporadic ALS. Here, I present our efforts to understand the mechanism of 
TDP-43 and FUS aggregation using pure proteins. 
In the absence of other components, both TDP-43 and FUS spontaneously 
assemble into pore-shaped oligomers and ordered filamentous structures 
that bear striking ultrastructural resemblance to the cytoplasmic inclusions 
in degenerating motor neurons of ALS patients. The structures formed by 
pure TDP-43 or pure FUS are non-amyloid in nature, just like the 
aggregates in ALS. Importantly, under identical conditions numerous other 
RNA-binding proteins remain soluble, suggesting this ordered assembly 
process is not a ubiquitous property of RNA-binding proteins. Rather, the 
primary sequences of FUS and TDP-43 contain specific determinants that 
confer the ability to form self-organizing filamentous structures. 
Indeed, we identified novel ‘prion-like’ domains in the N-terminal domain 
of FUS (residues 1-239) and in the C-terminal domain of TDP-43 (residues 
277-414) (Cushman et al., 2010. J. Cell Sci. 123, 1191-1201.). Similar to 
prion domains found in yeast prion proteins such as Sup35, this domain is 
enriched in uncharged polar amino acids (especially asparagine, glutamine 
and tyrosine) and glycine. For TDP-43, the C-terminal prion-like domain 
plays a major role in driving aggregation. Indeed, the majority of TDP-43 
mutations linked to ALS fall in the prion-like domain and accelerate the 
aggregation of pure TDP-43. For FUS, the N-terminal prion-like domain is 
also important for aggregation. However, additional C-terminal 
determinants, particularly the first RGG domain, are also critical, 
suggesting that FUS aggregates by a distinct mechanism to TDP-43. The 
majority of FUS mutations linked to ALS fall outside the prion-like domain 
and do not affect FUS aggregation kinetics. These key differences suggest 
that FUS and TDP-43, though similar RNA-binding proteins, likely 
aggregate and confer disease phenotypes via distinct mechanisms. 
The pure protein aggregation assays we have established for FUS and TDP-
43 provide a basic screening system to isolate specific molecules that 
antagonize and reverse their aggregation. As one example, we show that the 
Hsp104/Hsp70 chaperone system dissolves TDP-43 aggregates. 
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IMAGING NEURAL ACTIVITY WITH GENETICALLY ENCODED 
CALCIUM INDICATORS 
 
Lin Tian, Loren Looger  
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Ashburn, VA, 20147 
 
Understanding neural coding, learning and memory requires precise, 
simultaneous observation of multiple neurons in awake, behaving animals. 
These requirements can be met by optical recording of brain activity using 
genetically encoded calcium indicators (GECIs). Since they are encoded by 
DNA, GECIs can be delivered to the intact brain non-invasively, and 
targeted to defined populations of neurons and specific sub-cellular 
compartments for long-term, repeated, in vivo measurements. Over the last 
decade GECIs have been iteratively improved, and are now useful for 
quantitative imaging of neural activity in vivo. For example, GCaMP3 is 
being used to image large populations of neurons in behaving mice over 
months. Using GCaMP3 as an example, we describe the design and 
optimization of a GECI, including tuning indicators for specific 
applications. We will discuss the strengths and limitations of GCaMP3 in 
neural imaging, and propose strategies that might mitigate these limitations 
in next generation GECIs. 
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Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) 
comprise 4 proteins: GDNF, NRTN, ARTN and PSPN. They support 
survival and/or differentiation of distinct neuronal populations and protect 
them from injury. Therefore, GFLs are considered for the treatment of 
neurological disorders. GDNF and NRTN promote survival of 
dopaminergic neurons and thus have potential for the therapy of Parkinson's 
disease (PD). ARTN supports sensory and sympathetic neurons and holds 
promises for the management of chronic pain. PSPN may have impact in 
the therapy of stroke .  
GFLs signal through the receptor complex consisting of transmembrane 
receptor tyrosine kinase RET, which is shared by all 4 GFLs, and a ligand-
binding co-receptor GDNF family receptor α 1-4 (GFRα1-4) that is specific 
for each GFL. GFRα1 is specific for GDNF, GFRα2 - for NRTN, GFRα3 - 
for ARTN and GFRα4 - for PSPN. Some cross-talks also exist: GDNF can 
also bind to GFRα2, NRTN and ARTN to GFRα1.  
GDNF and NRTN have been tested in successful phase 1 clinical trials for 
PD. However, a larger placebo-controlled study failed to demonstrate a 
clear benefit of GDNF. The failure of GDNF in the last trial can be partly 
explained by its bad pharmacokinetic properties: GDNF, as well as NRTN 
and ARTN, have high affinity for the extracellular matrix and, therefore, 
restricted distribution in tissues. Thus, the alternatives to these proteins, 
such as small molecule GFL mimetics, are still in high demand in clinic. 
We developed the cell-based system for the selection of GFLs mimetics 
using luciferase as a reporter-gene. Luciferase expression in generated cells 
is controlled by the MAPK cascade which is in turn governed by 
GFRα1/RET or GFRα3/RET. To exclude molecules activating MAPK via 
other mechanisms we also made a RET-expressing cell line lacking any 
GFRα co-receptors. We proved the specificity and optimized the system for 
the high-throughput screening. We tested known agonists and antagonists of 
GFRα1/RET signalling to verify the applicability of the assay for the 
analysis of small molecules. Using our system we identified PSPN as a 
novel ligand for GFRα1/RET receptor complex. Since GFRα1/RET-
dependent signaling promotes the survival of dopaminergic neurons, PSPN 
can be considered as a candidate for PD therapy. Thus, we developed high 
throughput assay for identification of GFLs' mimetics, which can facilitate 
discovery of drugs against PD.  
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MODULATING ER STRESS TO INHIBIT ANIMAL PARKINSON 
DISEASE PROGRESSION 
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Parkinson Disease (PD) is a progressive neurodegenerative disorder that 
affects nearly 1% of the elderly population. The pathological hallmarks of 
PD include the loss of the dopaminergic neurons, the appearance of Lewy 
bodies and the activation of the unfolded protein response (UPR). Here, we 
present in vivo evidence that preconditioning the endoplasmic reticulum 
(ER) with mild stress response has strong neuroprotective effects in mice 
and flies PD models, and such effect is mediated through activation of 
autophagy We first show that intraperitoneal injection of tunicamycin, an 
inhibitor of protein glycosylation that induces UPR, results in the increase 
of XBP1 splicing and Bip expression in normal mouse brain, indicating that 
we have successfully administered a protective dose of tunicamycin that 
induces a mild ER stress response at a cellular level. We further observe 
that the tunicamycin treatment reduces dopaminergic neuron loss and 
ameliorates the Parkinson-like motor behaviour in mice treated with 6-
hydroxydopamine. Moreover, we are able to obtain similar finding in two 
models of Parkinson disease in Drosophila melanogaster. Specifically, we 
show that feeding flies with tunicamycin protected the neurons against 
damages induced by paraquat treatment or through neuronal expression of 
α-Syn. Based on these findings, we conclude that mild ER stress promotes 
cellular survival mechanisms that inhibit apoptosis. Furthermore, we 
demonstrate that mild ER stress induces autophagy only in the presence of 
an apoptotic signal in both mouse and Drosophila models. We propose that 
the inhibition of apoptosis by mild ER stress activates autophagy. Together 
our findings show that mild ER stress is neuroprotective and suggest that 
ER conditioning is a promising therapeutic avenue in Parkinson disease.  
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, east wing, lower level 
 PIN#:  Press 64570 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
